Podcasts about Lancet

Slovenski nefrolog sodeloval pri objavi treh člankov o kronični ledvični bolezni v znanstveni reviji Lancet.Ledvice lahko izgubljajo svojo funkcijo več let, ne da bi to opazili. Razvije se kronična ledvična bolezen (KLB), ki je po ocenah strokovnjakov ena najhitreje naraščajočih zdravstvenih težav sodobnega časa. Žal je pogosto spregledana, čeprav jo odkrije že enostavna analiza krvi in urina. O tem, kdo je najbolj ogrožen, kako poteka zgodnje odkrivanje bolezni in kakšne so možnosti zdravljenja, v Ultrazvoku govori nefrolog doc. dr. Andrej Škoberne (UKC Ljubljana). Dr. Škoberne je kot član mednarodne skupine strokovnjakinj in strokovnjakov v ugledni znanstveni reviji Lancet sodeloval pri objavi treh člankov, s katerimi splošno in strokovno javnost opozarjajo na pomen pravočasnega odkrivanja kronične ledvične bolezni. Na podlagi podatkov namreč ocenjujejo, da v razvitih državah kar od 30 do 50 odstotkov bolnikov s KLB še nima prepoznane bolezni. Originalni članki v znanstveni reviji Lancet: Članek 1 TUKAJ Članek 2 TUKAJ Članek 3 (drugopodpisan dr. Škoberne) TUKAJ Oddaja Ultrazvok - Nefrolog: Umetna inteligenca dokazala, da se ledvični bolniki pospešeno starajo TUKAJ  Foto: Andrej Škoberne/ UKC Ljubljana

Aaron Brown is a quantitative analyst, risk manager, and author of the new book Wrong Number: How to Extract Truth from a Blizzard of Quantitative Disinformation. https://amzn.to/4frmg3n He's also about to debate gun control at the Soho Forum in August — and his preparation for that debate is a pretty good preview of what's in the book. Topics include: why out of 28,000 gun control studies, the RAND Corporation found only 20 that weren't statistically crippled; the smoking analogy and what it tells us about legislation that runs ahead of evidence; why gun laws burden legitimate owners and not criminals; why we have a crime problem, not a gun problem; The Lancet paper that claimed US aid saved 92 million lives; how to spot three red flags that tell you a statistic is BS; and Wonder Bread's motto "Helps build strong bodies 12 ways" — which nobody ever actually wrote down. Get the book → Wrong Number: How to Extract Truth from a Blizzard of Quantitative Disinformation https://amzn.to/4frmg3n TIMESTAMPS: 0:00 — Intro — Aaron Brown and Wrong Number 0:34 — The Soho Forum gun control debate — and who he's up against 3:45 — The proposition: abolish all restrictions on adult firearm ownership 4:48 — Lou on navigating gun laws across state lines (NJ → PA → NY) 7:25 — The wide cultural divide: Scranton airport vs. any other airport with guns 9:04 — RAND Corporation: of 28,000 gun control studies, only 20 weren't crippled by errors 10:04 — The smoking analogy — legislation running ahead of the evidence 12:15 — Gun control laws only burden legitimate owners — not criminals 12:43 — The Glock switch ban and the AR-15 — targeting the popular, not the dangerous 15:18 — "Trump is a fascist" — and you want him to take the guns? 15:42 — Stop calling it a gun problem. It's a crime problem. 17:47 — We can identify the 1% of kids likely to commit 20–30% of violent crime 19:31 — Genetic markers for violence — and why that's controversial 20:48 — The Nordic prison model — does it work, and could it work here? 22:09 — Immigration data: why lumping everyone together gets you bad answers 25:20 — Lou's joke about open borders (for immigrants like his dad, not his cousins) 25:39 — Aaron's Jewish smuggler ancestors — blocked from junk dealing by licensing laws 27:04 — Did US aid really save 92 million lives? The Lancet paper that can't add up 29:13 — They saved 114% of the people — including 46M in China, which gets no aid 31:22 — Most published research findings are false — and we've known since 2005 32:42 — DOGE cuts and the "millions are dead" narrative 36:15 — Three red flags that tell you a statistic is BS 39:18 — Wonder Bread's "12 ways" — nobody ever wrote them down 40:18 — Outro — Wrong Number and the Soho Forum debate Watch full episodes on YouTube → https://www.youtube.com/watch?v=J4Vb53s4I0A&list=PLb5trMQQvT077-L1roE0iZyAgT4dD4EtJ Listen on Apple Podcasts → https://podcasts.apple.com/us/podcast/the-lou-perez-podcast/id1535032081 Listen on Spotify → https://open.spotify.com/show/2KAtC7eFS3NHWMZp2UgMVU  Lou's book — That Joke Isn't Funny Anymore: https://amzn.to/3VhFa1r  TheLouPerez.com |  info@thelouperez.com  Newsletter: https://substack.com/@louperez #Statistics #Misinformation #GunControl #USAID #AaronBrown #WrongNumber #SohoForum #LouPerezPodcast #LionsOfLiberty #DataLiteracy Learn more about your ad choices. Visit megaphone.fm/adchoices

Episode#337-Taped April 29, 2026 We talk about vaccines, pandemic preparedness and emerging infectious diseases. Vaccines remain one of the most powerful public health tools that we have. A 2024 Lancet study estimated that global immunization efforts saved 154 million lives over the past 50 years- that's about 6 lives every minute. Joining us is Dr. Amesh Adalja MD, a board-certified infectious diseases, critical care, emergency medicine, senior scholar at the Johns Hopkins Center for Health Security. He is also an affiliate of the Johns Hopkins Center for Global Health. Dr. Adalja will discuss with us evidence-based insights on vaccines and their importance in our lives and health and well-being. Are we pandemic prepared? And what can we do as individuals to protect ourselves and have long-term health protection. To get in touch with Amesh Adalja MD and learn all about him and his work, go to www.ameshadalja.com Check out Dr. Amesh Adalja www.ameshadalja.com It's All About Health & Fitness-Vicki Doe Fitness podcast Ranked on the Top 25 Midwest Fitness Podcasts to Listen to… with additional national recognition on the Top 100 US fitness podcast. Rate This Podcast Give us a 5-star review.  We appreciate you! Take this quick audience survey. Thank you! FREE Metabolic Makeover Masterclass Webinar Replay! Learn how to reset your metabolism, boost energy, and support sustainable weight loss using simple, science-backed strategies. Enroll in the Vicki Doe Fitness Academy to get instant access to the replay and begin your healthy living journey today. Vicki Doe Fitness-STORE Discover the Vicki Doe Fitness-STORE—your destination for stylish apparel, fitness gear, and wellness essentials like yoga mats, water bottles, candles, and premium supplements. Shop now and elevate your health journey! Resources *Note: Some of the resources below may be affiliate links, meaning Vicki Doe Fitness receives a commission (at no extra cost to you) if you use the link to make a purchase. Thank you for your support! Herbs and spices are the keys to delicious, flavorful, and sophisticated meals! FREE DOWNLOAD- Herbs and Spices Cheatsheet Let's get ECO-friendly.  Try ECOLunchbox.com ECOlunchbox specializes in stainless steel bento boxes, artisan fair trade lunch bags, napkins, snack sacks, and other eco-friendly lunchware. They are a certified green business.  ECOlunchbox is a consumer products company started by an eco mom in the San Francisco Bay Area. ECOLunchbox.com Go to our Resources page-   For the most recommended tools, you need to succeed on your healthy living journey!! Listen and share our podcast show- “It's All About Health & Fitness-” Vicki Doe Fitness Subscribe to Apple Podcast Subscribe on Stitcher Or on any of the platforms that you listen to your podcast! Watch & Subscribe on YouTube! Catch our latest health & wellness videos on YouTube at Vicki Haywood Doe – Vicki Doe Fitness YouTube-Vicki Haywood Doe-Vicki Doe Fitness Join us to receive a health wellness message!

From rubber bands and metal clips to fabric-covered elastics and slick buns, this episode explores how everyday accessories affects hair. We breakdown the mechanical and biological cost of tight, rough, or poorly chosen accessories, including breakage and hair loss.Tune in to learn how to choose better, style smarter, and protect your hair goals without losing your personality.Listen now and rethink your hair accessories.Download your free copy of the UTK-Podcast Hair Accessory Guide for hair accessory tips to support your hair goals.ReferencesBolduc, C., & Shapiro, J. (2001). "Management of hair loss." The Lancet, Vol. 357, Issue 9253, pp. 321-322. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(00)03630-1/fulltextDraelos, Z. D. (2010). "Essentials of Hair Care often neglected: Hair Cleansing." Journal of Cosmetic Dermatology, Vol. 9, Issue 4, pp. 312-315. https://onlinelibrary.wiley.com/journal/14732165Khumalo, N. P., et al. (2007). "Traction alopecia is caused by hair care practices." Journal of the American Academy of Dermatology, Vol. 57, Issue 2, pp. 221-230. https://www.jaad.org/article/S0190-9622(07)00583-1/fulltextMiteva, M., & Tosti, A. (2013). "Traction Alopecia." Dermatologic Clinics, Vol. 31, Issue 1, pp. 107-117. https://www.derm.theclinics.com/article/S0733-8635(12)00101-3/fulltextSwift, J. A. (1991). "The mechanics of fracture of human hair." Journal of the Society of Cosmetic Chemists, Vol. 42, pp. 1-18. https://library.scconline.org/v042n01/Send us Fan MailSend your questions about Afro-textured/coily hair to utkinhair@gmail.com.Check out your natural beauty hub, ÈYÍ DÁRA Naturals for natural hair care solutions.Follow us on instagram @utkpodcast

Get Myoscience Creatine and Magnesium (20% off) HERE: https://bit.ly/4ocjMbp  Pre-order Keto Flex Revised and get free bonuses: https://bit.ly/4wKG1sM    Men today are walking around with 20 to 30% less testosterone than their fathers had at the exact same age. Not because of disease. Because of five everyday habits that modern men think are completely normal. In this episode, I'm breaking down the five silent mistakes that are aging men faster than anything else right now, the science behind why they're so damaging, and the exact daily stack I personally use to fight back. I'm 41 years old and I've watched this happen to men I love. The decline doesn't announce itself. But it can be reversed. Key Takeaways: Men today have 20 to 30% less testosterone than men of the same age in 1988, per the Massachusetts Male Aging Study Grip strength predicts death more accurately than blood pressure, per a Lancet meta-analysis of 140,000 people One week of sleeping 5 hours or less drops testosterone by 10 to 15%, the equivalent of aging 10 to 15 years Sitting for long hours thins the memory center of the brain, and exercise does not offset this damage 85-year-olds gained muscle and reversed fiber-level aging in 12 weeks of resistance training in a Mayo Clinic study The five mistakes: stopping explosive movement, stopping brain challenges, ignoring muscle decline, neglecting recovery, and accepting decline as normal The simple daily stack: outdoor walks, heavy lifting twice a week, one gram of protein per pound of ideal body weight, 7+ hours of sleep, creatine, magnesium, and weekly brain challenges Find All The Ben Azadi Show Sponsorship Deals ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.ketokamp.com/sponsorship-deals Learn more about your ad choices. Visit megaphone.fm/adchoices

A guide to diagnosing, imaging, and managing acute renal colic and nephrolithiasis in the ED. Hosts: Brian Gilberti, MD Avir Mitra, MD https://media.blubrry.com/coreem/content.blubrry.com/coreem/Nephrolithiasis.mp3 Download Leave a Comment Tags: Kidney Stones, Urology Show Notes 1. CLINICAL CORE & PHYSIOLOGIC FRAMEWORK Epidemiologic Risk Profiles Lifetime incidence parameters hover around 1 in 11, presenting with a prominent male sex skew. Peak demographic manifestation concentrated within the 30–60 age band. High-yield temporal parameter: 50% recurrence vector within a 5-year post-initial-insult window. Mineralogical Composition Vectors Calcium oxalate crystals represent the predominant structural matrix. Struvite configurations (magnesium ammonium phosphate matrix) account for 1–2% of cohorts. Struvite stones function explicitly as infection-driven configurations secondary to upper tract proliferation; higher distribution index noted in female cohorts. Etiological & Modifiable Relational Dynamics Profound systemic dehydration or low baseline fluid throughput states. High-sodium diet structures and heavy animal-protein consumption loads. Positive genetic/familial history variables. Relative risk modulation: Each variable independently operates to expand baseline risk by a factor of 2x to 3x. Pathophysiologic Symptom Complexes Acute, sudden-onset, maximum-intensity (10/10) unilateral flank pain. Classic structural radiation vector tracking downward toward the ipsilateral groin/genitourinary dermatomes. Distinctive behavioral marker: Renal colic pacing/writhing behavior with zero antalgic position availability. Concomitant autonomic triggers: Nausea and emesis manifest in 50% of acute presentations. Physical Exam Discordance Metrics Severe subjective distress contrasted with a characteristically soft, completely non-tender abdominal palpation exam. CVA tenderness is completely variable and lacks reliable negative predictive value. Atypical Presentation Classifications Vague, poorly localized abdominal pain presentations occurring in up to 20% of active cases. Isolated lower urinary tract irritative signs including acute frequency or severe urgency. Incidental & Asymptomatic Dynamics Silent intrarenal or ureteral stones found incidentally. Longitudinal tracking demonstrates up to 33.3% of initially asymptomatic cohorts convert to fully symptomatic renal colic within a multi-year tracking window. 2. EXCLUSION DIAGNOSES & CRITICAL PATHWAY RED FLAGS Vascular Mimics: AAA rupture/expansion. This is a mandatory exclusion pathway in elderly cohorts presenting with acute flank or back pain. Physical tracking requires active exploration for an expansile, pulsatile abdominal mass. Gynecologic Emergencies: Ruptured ectopic pregnancy. Demands universal screening protocols via rapid beta-hCG testing in all female patients of childbearing potential presenting with lower abdominal/pelvic localization. Infectious Upper Tract Decompensation: Acute uncomplicated pyelonephritis. Differentiated via persistent high spikes, high fevers, systemic shaking chills, and profound pyuria. Genitourinary Structural Crises: Acute testicular torsion. Mandates a thorough, explicit scrotal/testicular structural exam if the flank pain radiates into the scrotum. Gastrointestinal and Adnexal Torsional Confounds: Acute appendicitis variants, acute mesenteric/bowel ischemia, and ovarian torsion syndromes. 3. LABORATORY TESTING & PHYSIOLOGIC EVALUATION Urinalysis Interpretation Nuances Microscopic or gross hematuria presents in approximately 66% to 90% of acute cases. Critical Pathological Caveat: Complete absence of hematuria documented in 20% to 33.3% of confirmed, acute obstructing ureteral stones. Diagnostic rule: A pristine urinalysis with zero red blood cells is entirely insufficient to exclude acute ureterolithiasis. Urinary pH as a Composition Clue Consistently low urinary pH parameters (pH < 5.5) point strongly toward a uric acid crystalline composition. Elevated urinary pH parameters (pH > 7.5) indicate the presence of urease-producing microbial pathogens, pointing toward a struvite infection stone. Infectious Screening Metrics Active tracking for marked pyuria, positive leukocyte esterase, and bacterial nitrites to rule out an obstructed, infected upper urinary tract system. BMP Immediate quantification of baseline serum creatinine to establish accurate eGFR values. Targeting detection of post-renal AKI from bilateral obstruction, unilateral obstruction in a single functioning kidney, or severe volume depletion. CBC Evaluation for marked leukocytosis. Physiologic Nuance: Mild-to-moderate white blood cell count elevations frequently represent non-specific stress demargination driven by severe pain and repetitive vomiting. High-grade white blood cell shifts demand immediate exclusion of systemic bacteremia or an infected, obstructed urinary system. Adjunctive Lab Pathways Rapid qualitative urine hCG testing. Reflex urine culture execution whenever urinalysis metrics display significant inflammatory profiles or clinical suspicion of UTI is high. 4. IMAGING MODALITIES & ALGORITHMIC CLINICAL SELECTION Non-Contrast CT Diagnostics Gold standard; diagnostic sensitivity and specificity parameters exceed 95% for stones >2 mm. Provides precise quantification of stone diameter (mm), exact localization (proximal, mid, or distal ureter), and degree of secondary hydronephrosis. Excellent structural visualization for detecting or ruling out alternate retroperitoneal, vascular, or intra-abdominal pathologies. Contrast-Enhanced CT Protocols Indicated when alternative intra-abdominal surgical pathology is highly suspected over isolated renal colic. Retains diagnostic capability to identify urinary tract stones >3 mm even within contrast-enhanced phases. NCCT Structural Architecture Limitations Standard stone protocol CT scans are executed in a prone position without IV contrast enhancement. It does not opacify the ureteral lumen. Presents a cumulative radiation exposure penalty when utilized serially across recurrent ED presentations. POCUS / Radiology Ultrasound Direct stone visualization capabilities are modest, operating at approximately 50% to 60% sensitivity, and is highly dependent on anatomical positioning at the extreme proximal ureter or the UVJ. Secondary obstruction tracking: Demonstration of hydronephrosis operates at a high sensitivity of approximately 80%. POCUS Clinical Utility Metrics Eliminates ionizing radiation exposure and allows immediate, rapid real-time execution directly at the patient’s bedside. Confirmation of significant hydronephrosis within a classic clinical presentation yields high post-test probability for stone presence while lowering suspicion for vascular catastrophes like a AAA. KUB Radiography Extremely poor overall diagnostic sensitivity, hovering around 57%. Fails to image radiolucent configurations (pure uric acid matrices) or small stones measuring

Fontes do episódio aqui:⁠https://portal.afya.com.br/podcasts/afya-news/08-06-2026Nesta segunda-feira, o boletim analisa novas fronteiras oncológicas para os análogos de GLP-1, o avanço das terapias incretínicas combinadas e o impacto histórico da triagem neonatal no Brasil . Começamos com os estudos apresentados na ASCO que sugerem uma associação entre os agonistas de GLP-1 e a redução do risco de alguns tipos de cancro e da progressão tumoral. Detalhamos o ensaio clínico publicado no The Lancet sobre a combinação de cagrilintida e semaglutida (CagriSema), que demonstrou melhoria robusta no controlo glicémico e na perda de peso em doentes com diabetes tipo 2. Por fim, no Radar, celebramos os 25 anos do Teste do Pezinho no SUS, reforçando a importância do diagnóstico precoce e do aproveitamento da janela terapêutica neonatal. Afya News. Informação médica confiável e atualizada no seu tempo.

Un nouvel épisode du Pharmascope est disponible! Dans ce 178e épisode, Nicolas, Olivier et Amélie tentent de pondre des réponses un tant soi peu intelligentes à vos excellentes questions. Nous discutons d'ajustement de lévothyroxine, du suivi des IECA/ARA, du rôle de la cariprazine et de l'impact des inhibiteurs du SGLT-2 sur le magnésium.   Les objectifs pour cet épisode sont les suivants: Discuter des modalités d'ajustement de la lévothyroxine et de la déprescription potentielle de celle-ci Discuter des suivis de laboratoire suivant l'initiation d'un ARA ou d'un IECA Discuter des évidences portant sur l'utilisation de la cariprazine Discuter de l'impact des  inhibiteurs du SGLT-2 sur le magnésium Ressources pertinentes en lien avec l'épisode Jonklaas J, et coll; American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014 Dec;24(12):1670-751. Van Uytfanghe K, et coll. Thyroid Stimulating Hormone and Thyroid Hormones (Triiodothyronine and Thyroxine): An American Thyroid Association-Commissioned Review of Current Clinical and Laboratory Status. Thyroid. 2023 Sep;33(9):1013-1028. Ravensberg J, et coll. Discontinuation of Levothyroxine in Adults Aged 60 Years or Older. JAMA. 2026 Apr 6;335(17):1491–8. RPE de néphrologie de l'APES. Place des IECA et des ARA dans le traitement de la maladie rénale chronique. Septembre 2025. Bhandari S, et coll; STOP ACEi Trial Investigators. Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease. N Engl J Med. 2022 Dec 1;387(22):2021-2032. Clase CM, et coll. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes. Kidney Int 2017;91:683-90. Garlo KG, et coll. Association of changes in creatinine and potassium levels after initiation of renin angiotensin aldosterone system inhibitors with emergency department visits, hospitalizations, and mortality in individuals with chronic kidney disease. JAMA Netw Open 2018;1:e183874. Monographie de produit, Abbvie. VRAYLAR (cariprazine). Canada, 6 mars 2024. Barabassy A, et coll. Transdiagnostic Efficacy of Cariprazine: A Systematic Review and Meta-Analysis of Efficacy Across Ten Symptom Domains. Pharmaceuticals (Basel). 2025 Jul 2;18(7):995. Németh G, et coll. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017 Mar 18;389(10074):1103-1113. Fava M, et coll. Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol. 2018 Nov;33(6):312-321. Durgam S, et coll. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry. 2016 Mar;77(3):371-8. Barabassy A, Csehi R, Dombi ZB, Szatmári B, Brevig T, Németh G. Transdiagnostic Efficacy of Cariprazine: A Systematic Review and Meta-Analysis of Efficacy Across Ten Symptom Domains. Pharmaceuticals (Basel). 2025 Jul 2;18(7):995. Zhang J, et coll. Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Serum Electrolyte Levels in Patients with Type 2 Diabetes: A Pairwise and Network Meta-Analysis of Randomized Controlled Trials. Kidney360. 2022 Jan 19;3(3):477-487. Toto RD, et coll. Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials. J Diabetes Complications. 2019 Oct;33(10):107402.

ThePrintPod: Alzheimer's may show up in blood yrs before symptoms appear—Lancet study offers hope of early diagnosis

One in six teenagers right now has measurable hearing loss, and almost nobody is talking about it. In this conversation with Brandon Sawalich of Starkey Hearing Technologies, we pull back the curtain on what Brandon calls a “quiet pandemic” driven by earbuds, concerts, and a generation blasting sound directly into their cochlea. If you're still pounding music through your earbuds on a daily basis, this episode is your wake-up call. CLICK HERE TO BECOME GARY'S VIP!: https://bit.ly/4ai0Xwg Connect with Brandon Sawalich Website: https://bit.ly/4mOv98w  Website: https://bit.ly/42ASAc4  Instagram: https://bit.ly/4cPsNlc  Facebook: https://bit.ly/42w3wb3  X: https://bit.ly/41TWYmr  LinkedIn: https://bit.ly/4u6JYFV  Thank you to our partners A-GAME: “ULTIMATE15” FOR 15% OFF: http://bit.ly/4kek1ij  AION: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4h6KHAD  AIRES: "ULTIMATE20 " FOR 20% OFF: https://bit.ly/4a3Duze  BAJA GOLD: "ULTIMATE10" FOR 10% OFF: https://bit.ly/3WSBqUa  BODYHEALTH: “ULTIMATE20” FOR 20% OFF: http://bit.ly/4e5IjsV  COLD LIFE: THE ULTIMATE HUMAN PLUNGE: https://bit.ly/4eULUKp  CYMBIOTIKA: "ULTIMATE10" FOR 10% OFF: https://bit.ly/4tjyluP  GENETIC METHYLATION TEST (UK ONLY): https://bit.ly/48QJJrk  GENETIC TEST (USA ONLY): ⁠https://bit.ly/3Yg1Uk9  GOPUFF: GET YOUR FAVORITE SNACK!: https://bit.ly/4obIFDC  H2TABS: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4hMNdgg  HEALF: 10% OFF YOUR ORDER: https://bit.ly/41HJg6S  PEPTUAL: “TUH10” FOR 10% OFF: https://bit.ly/4mKxgcn  SNOOZE: LET'S GET TO SLEEP!: https://bit.ly/4pt1T6V  WHOOP: JOIN & GET 1 FREE MONTH!: https://bit.ly/3VQ0nzW  Watch  the “Ultimate Human Podcast” every Tuesday & Thursday at 9AM EST: YouTube: https://bit.ly/3RPQYX8 Podcasts: https://bit.ly/3RQftU0 Connect with Gary Brecka Instagram: https://bit.ly/3RPpnFs TikTok: https://bit.ly/4coJ8foX: https://bit.ly/3Opc8tf Facebook: https://bit.ly/464VA1H LinkedIn: https://bit.ly/4hH7Ri2 Website: https://bit.ly/4eLDbdU Merch: https://bit.ly/4aBpOM1 Newsletter: https://bit.ly/47ejrws Ask Gary: https://bit.ly/3PEAJuG Timestamps 00:00 ​Intro of Show 03:03 Link between Hearing and Brain Health 08:35 Hearing Loss is Irreversible 09:59 Hearing Aids: Technology 13:17 Causes of Hearing Loss and Tinnitus  18:39 Mitigating Tinnitus 20:34 Starkey Hearing Technologies 23:29 How Often Should You Test Your Hearing? 27:04 Risk Factors for Hearing Loss 32:13 Hearing Issues Change One's Personality 32:56 Connect with Brandon and Starkey 35:12 Lancet study: https://bit.ly/4ekLQ8V  35:52 What Does It Mean to You to Be an Ultimate Human? The information provided here is for general informational purposes only and should not be considered as medical or clinical advice. It is not intended to diagnose, treat, cure, or prevent any health condition, and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of your physician or other qualified health provider with any questions you may have regarding a medical condition or health objectives. The use of any information provided is solely at your own risk, and the provider of this information is not liable for any consequences arising from its use.   Disclosure: Some links to certain products or services are affiliate links, meaning we may earn a commission. Gary Brecka is the owner of Ultimate Human, LLC which operates The Ultimate Human podcast and promotes certain third-party products used by Gary Brecka in his personal health and wellness protocols and daily life and for which Ultimate Human LLC and / or Gary Brecka directly or indirectly holds an economic interest or receives compensation. Accordingly, statements made by Gary Brecka and others (including on The Ultimate Human podcast) may be considered promotional in nature. Learn more about your ad choices. Visit megaphone.fm/adchoices

Forget muscle repair. The reason sleep actually transforms your health is happening inside your skull every night — and it's not what Matthew Walker's TED Talk made famous. In this episode of Health Longevity Secrets, Robert Lufkin MD breaks down the real science of sleep: the glymphatic system that flushes beta-amyloid from your brain, the hippocampal "sharp wave ripples" that lock in memories, the slow-wave growth hormone pulse you can't make up, and the testosterone and insulin damage that happens in a single week of short sleep. He closes with the single most evidence-based intervention you can do tonight — and it's not melatonin. CHAPTERS: 00:00 — Why The "Sleep For Muscle Repair" Story Is Wrong 01:00 — Part 1: The Muscle Repair Myth (mTOR, Protein Synthesis, 24–48hr Window) 02:00 — Part 2: The Molecular Truth — The Glymphatic System 02:35 — The 60% Brain Cleaning Cycle (Xie 2013, Beta-Amyloid Clearance) 03:30 — Sharp Wave Ripples and Memory Consolidation in Deep Sleep 03:55 — How Sleep Onset Drives 70% of Your Nightly Growth Hormone 04:30 — Sleep Restriction Drops Testosterone 10–15% in One Week 05:00 — Part 3: The Hormonal Layer — Insulin, Cortisol, Ghrelin 05:15 — 4 Nights, 4 Hours: Prediabetes In Healthy Young Men (Spiegel 1999) 06:30 — Ghrelin, Leptin, and Why You Wake Up Hungrier 07:00 — Part 4: The Practical Tactic — Thermal Regulation 07:30 — The 2–3°F Core Temperature Drop That Triggers Sleep 08:00 — Why a Hot Shower 90 Minutes Before Bed Beats Melatonin 08:45 — The 65–68°F Bedroom Rule 09:15 — Part 5: The Reframe — Sleep Is Neurological, Not Muscular KEY TAKEAWAYS: • Muscle protein synthesis runs 24–48 hours post-workout and does not require sleep architecture — it requires amino acids, energy, and time. • During sleep, your brain's interstitial space expands ~60% to flush metabolic waste, including the beta-amyloid and tau proteins implicated in Alzheimer's. • ~70% of your daily growth hormone is released in the first slow-wave cycle — disrupt the first 90 minutes and you blunt the whole night. • Four nights of 4-hour sleep produced prediabetes-level insulin resistance in healthy young men (Spiegel et al., Lancet 1999). • A hot bath or shower 60–90 minutes before bed shortens sleep latency more reliably than melatonin (Haghayegh et al., Sleep Medicine Reviews 2019). Pair with a 65–68°F bedroom. STUDIES & SOURCES MENTIONED: • Xie L, et al., Science 2013 — Sleep drives beta-amyloid clearance via the glymphatic system — https://pubmed.ncbi.nlm.nih.gov/24136970/ • Spiegel K, Leproult R, Van Cauter E, Lancet 1999 — Sleep debt and metabolic/endocrine function (4-night 4-hour sleep restriction trial) — https://pubmed.ncbi.nlm.nih.gov/10543671/ • Leproult R, Van Cauter E, JAMA 2011 — 1 week of sleep restriction drops testosterone 10–15% in healthy young men — https://pubmed.ncbi.nlm.nih.gov/21632481/ • Haghayegh S, et al., Sleep Medicine Reviews 2019 — Warm shower/bath 1–2h before bed shortens sleep onset latency (meta-analysis of 13 trials) — https://pubmed.ncbi.nlm.nih.gov/31102877/ • Pontzer H, et al., Current Biology 2016 — Constrained total energy expenditure model — https://pubmed.ncbi.nlm.nih.gov/26832439/ • Walker M, "Why We Sleep" (book) — https://en.wikipedia.org/wiki/Why_We_Sleep ─────────────────────────────────

In this episode of Mind the Meds, Erica Marini, PharmD, highlights information from the European Stroke Organization Conference include encouraging data on asundexian(Bayer), a factor XIa inhibitor showing reduced recurrent ischemic stroke risk without increased bleeding, as well as positive results from three trials of tirofiban in acute ischemic stroke settings. On the multiple sclerosis (MS) front, Marini covers the FDA approval of ocrelizumab (Ocrevus; Genentech) for pediatric relapsing-remitting MS in children 10 and older, a new study supporting early use of high-efficacy agents in pediatric MS, and 2 Lancet publications on ocrelizumab — one examining higher weight-adjusted dosing (which did not improve disability progression) and one confirming benefit in a broader primary progressive MS population. She also briefly discusses PADOVA (NCT04777331), a phase 2b trial of prasinezumab in early Parkinson's disease, which failed to meet its primary end point.The bulk of the episode is a discussion with guest Millad Sobhanian, PharmD, BCPS, clinical pharmacy specialist in neurology at the University of Maryland, focused on Alzheimer disease. They cover dextromethorphan/bupropion (Auvelity; Axsome Therapeutics), newly approved in April 2026 for agitation associated with Alzheimer dementia. Sobhanian walks through key safety considerations—including additive NMDA antagonism if combined with memantine, cardiovascular risks from the bupropion component, and the ever-present black box warning on antipsychotics in dementia patients—while both note that the efficacy data, though statistically significant, shows modest clinical effect sizes compared to the threshold for meaningful within-patient change.The conversation then turns to lecanemab's subcutaneous initiation formulation (Leqembi Iqlik; Eisai, Biogen), whose FDA decision has been delayed to about August 2026 as regulators seek more data on bioavailability and ARIA monitoring in the at-home setting. Sobhanian shares his real-world perspective on anti-amyloid therapy, describing a patient population that is typically early-stage, high-functioning, and has a mean age of about 60 to 70 years, and emphasizing the pharmacist's role in expectation-setting around the modest but potentially cumulative slowing of cognitive decline. The episode closes with a thorough discussion of the April 2026 Cochrane review on amyloid-targeting monoclonal antibodies, which both Marini and Sobhanian find overly broad in its conclusions. They note limitations such as the inclusion of withdrawn agents like aducanumab (Aduhelm; Biogen), heterogeneous inclusion criteria across trials, and an 18-month study horizon that may be too short to capture the full benefit suggested by longer-term open-label extension data.Key Takeaways:1. New options for Alzheimer's agitation exist, but fit carefully into the treatment algorithm. Dextromethorphan/bupropion offers a novel NMDA-based mechanism for treating agitation in Alzheimer dementia, but its clinical effect size is modest, and it carries meaningful safety considerations—particularly around the bupropion component in elderly patients. Like all pharmacologic options in this space, it remains a later-line choice after nonpharmacologic interventions have been exhausted, and medication reconciliation is critical given its interaction potential with memantine and CYP2D6 inhibitors.2. Anti-amyloid therapies are imperfect but not ready to be written off. The April 2026 Cochrane review drew significant attention with its conclusion that anti-amyloid monoclonal antibodies produce only trivial cognitive benefits, but its findings are limited by the inclusion of older, withdrawn agents, heterogeneous trial populations, and an 18-month time horizon that may be too short to capture the full trajectory of benefit.3. The pharmacist's role in anti-amyloid therapy goes well beyond dispensing. As illustrated by Sobhanian's practice at the University of Maryland, clinical pharmacists embedded in neurology clinics play a critical role in patient selection, expectation-setting, ARIA counseling, and informed decision-making for patients considering anti-amyloid therapy—a complex, high-stakes treatment decision that these patients and their caregivers should never be navigating alone.

Welcome to the latest episode (June 2026) of Diabetes Core Update, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month on DOC Update: Shah S, et al. "Food Coloring Additives and Incidence of Type 2 Diabetes in the NutriNet-Santé Prospective Cohort Diabetes Care. 2026;49(6):1067–1077. doi.org/10.2337/dc25-2727 Hespanhol L, et al. "Automated Insulin Delivery Systems in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis." Diabetes Care. 2026;49(6):1134–1143. doi.org/10.2337/dc25-2435 Tatum K, et al. "Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer." JAMA. Published Online: May 11, 2026 2026;9;(5):e2612133. doi:10.1001/jamanetworkopen.2026.12133 Winkler C, et al. "Screening Children for Early-Stage Type 1 Diabetes." JAMA. Published Online: May 21, 2026 doi:10.1001/jama.2026.6085 Würtz Yazdanfard P, Kosjerina V, Wood-Kurland H et al. "Effectiveness and Safety of Semaglutide in Type 1 Diabetes: A Danish Nationwide Cohort Study (2018–2024)" Lancet. Volume 66, 101716, July 2026. doi:10.1016/j.lanepe.2026.101716 Horn D, Aronne L, Wharton S et al. "Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial." Lancet. Published online May 12, 2026. doi:10.1016/S0140-6736(26)00656-2 Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, click here.

Near-death experiences (NDE) are often described in spiritual, personal or even supernatural terms. But a new CMAJ article offers physicians a clinical entry point into understanding them as a distinct phenomenon that patients may report after cardiac arrest, critical illness or other life-threatening events.Dr. Blair Bigham and Dr. Mojola Omole speak with Dr. Andrés Delgado-Ron, a senior data analyst at Simon Fraser University's Faculty of Health Sciences and author of “Five things to know about near-death experiences”. He explains how NDEs differ from delirium or hallucinations, why they are often described as highly organized and vivid, and how veridical perceptions, where patients report details that can later be verified, raise important questions for researchers and clinicians.They also speak with Dr. Marieta Pehlivanova, research assistant professor of psychiatry and neurobehavioural science at the University of Virginia Division of Perceptual Studies, about how physicians respond when patients disclose these experiences. She explains why dismissive reactions can be harmful, how they may prevent patients from processing an event that feels profound, and why clinicians can validate the experience without needing to explain or endorse every aspect of it.For physicians, the message is practical: stay curious, listen without judgement and avoid automatically pathologizing or brushing aside a patient's account. Patients may need space to talk about what happened, and clinicians can offer that space while still maintaining scientific rigour.Lancet article discussed.Comments or questions? Text us.Join us as we explore medical solutions that address the urgent need to change healthcare. Reach out to us about this or any episode you hear. Or tell us about something you'd like to hear on the leading Canadian medical podcast.You can find Blair and Mojola on X  @BlairBigham and @DrmojolaomoleX (in English):  @CMAJ X (en français): @JAMC FacebookInstagram: @CMAJ.ca The CMAJ Podcast is produced by PodCraft Productions

Brjóstakrabbamein er algengasta tegund krabbameins hjá íslenskum konum og er nærri þriðjungur af öllum meinum sem greinast. Niðurstöður nýrrar alþjóðlegrar rannsóknar gefa til kynna að með erfðaprófum sé hægt að meta líkurnar á gagnsemi lyfjameðferðar. Slík erfðapóf eru notuð hér og Halla Þorvaldsdóttir framkvæmdastjóri Krabbameinsfélagsins segir að íslenskir sjúklingar njóti góðs af. Um 1.2 milljarðar Jarðarbúa, 1.200 milljónir karla, kvenna og barna, eru með geðsjúkdóma eða geðraskanir af einhverju tagi. Það eru nær tvöfalt fleiri en 1990. Það þýðir að geðraskanir eru algengasta heilbrigðisvandamál samtímans. Þetta er meginniðurstaða viðamikillar rannsóknar sem birt var í læknatímaritinu Lancet á dögunum. Bresk stjórnvöld birtu í dag skjöl í þremur bindum upp á um fimmtán hundruð síður með samskiptum sem tengjast sendiherratíð Peters Mandelsonsa í Bandaríkjunum. Ýmislegt í skjölunum er talið koma illa við Keir Starmer sem þegar sætir mikilli gagnrýni vegna skipunar Mandelsons.

Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Dr Hedvig Hricak (Memorial Sloan Kettering Cancer Center, New York, NY, USA) and Dr Zachary Ward (Harvard TH Chan School of Public Health, Boston, MA, USA) to discuss Cancer workforce—a global crisis: a Lancet Oncology Commission. To discover more about the commission click here: www.thelancet.com/commissions-do/cancer-workforce. To read the full commission click here: https://doi.org/10.1016/S1470-2045(26)00065-3

In this episode of The Lancet In Conversation With, editors Niall Boyce and Bea Gómez Pérez-Nievas are joined by three leading researchers to discuss highlights from The Lancet's special issue on neurology. The conversation covers three landmark studies: the PADOVA trial of prasinezumab in early-stage Parkinson's disease, the ORATORIO-HAND study extending ocrelizumab treatment to wheelchair-using patients with progressivemultiple sclerosis, and the HEAD study comparing tau PET tracers in Alzheimer's disease — each representing a significant step forward in the field. The guests also reflect on the broader forces reshaping neurology: the push toward earlier, biomarker-guided intervention, cross-specialty learning between the multiple sclerosis, Alzheimer's, and Parkinson's fields, and emerging platforms such as CAR T-cell therapies and blood-based biomarkers. From the transformative success of spinal muscular atrophy treatment to the prospect of an EBV vaccine preventing MS, the discussion strikes a note of cautious optimism about a specialty that is entering a new therapeutic era. Visit the lancet.com to discover more

Klein, W., Li, S., & Wood, S. (2023). A qualitative analysis of gaslighting in romantic relationships. Personal Relationships, 30(4), 1316-1340.Specifically talk about it around 25 minutes  and 42 minutes Klein, W., Wood, S., Forget, A. A., & Bartz, J. A. (2026). A historical review of gaslighting: Tracing changing conceptualizations within psychiatry and psychology. Clinical Psychology Review, 102742.Was under review when we filmed - accepted and early access now Klein, W., Wood, S., & Bartz, J. A. (2026). A theoretical framework for studying the phenomenon of gaslighting. Personality and Social Psychology Review, 30(2), 195-215.I call it the 2025 paper, cause it was accepted and early access online in 2025, but I guess now it gets 2026 in the citation info, because the issue its technical in is the January issue. Which is annoying, because it's cited as 2025 in some places lol. Info on other stuff I brought uphttps://www.amazon.ca/This-Your-Brain-Music-Obsession/dp/0452288525Barton, R., & Whitehead, J. A. (1969). THE GAS-LIGHT PHENOMENON. The Lancet, 293(7608), 1258–1260. https://doi.org/10.1016/S0140-6736(69)92133-3First psychiatric gaslighting paper, don't think its open access thoughStark, C. A. (2019). Gaslighting, misogyny, and psychological oppression. The monist, 102(2), 221-235.11 minute mark - reasonable disagreement - I thin it's open accessClark, A. (2013). Whatever next? Predictive brains, situated agents, and the future of cognitive science. Behavioral and Brain Sciences, 36(3), 181–204. https://doi.org/10.1017/S0140525X12000477Around the 19 minute mark de Bruin, L., & Michael, J. (2021). Prediction error minimization as a framework for social cognition research. Erkenntnis, 86(1), 1-20.Also around the 19 minute mark Friston, K. (2010). The free-energy principle: a unified brain theory?. Nature reviews neuroscience, 11(2), 127-138.Around the 22 min mark Ogunfowora, B., & Bourdage, J. S. (2026). Is My Boss Gaslighting Me? Uncovering the Nomological Network of Gaslighting In Leader-Employee Relationships. Journal of Management, 01492063261426014.Workplace gaslighting 29 minute markBashford, J., & Leschziner, G. (2015). Bed partner “gas-lighting” as a cause of fictitious sleep-talking. Journal of Clinical Sleep Medicine, 11(10), 1237-1238.Contemporary case study discussed around 30 minute mark Bellomare, M., Giuseppe Genova, V., & Miano, P. (2024). Gaslighting exposure during emerging adulthood: Personality traits and vulnerability paths. International journal of psychological research, 17(1), 29-39.Miano, P., Bellomare, M., & Genova, V. G. (2021). Personality correlates of gaslighting behaviours in young adults. Journal of Sexual Aggression, 27(3), 285-298.2 papers on personality and gaslighting - 35 minute mark Graves, C. G., & Samp, J. A. (2021). The power to gaslight. Journal of Social and Personal Relationships, 38(11), 3378-3386.Gaslighting and power  35 minute mark https://www.amazon.com/Gaslighting-Interrogation-Methods-Psychotherapy-Analysis/dp/1568218281Covert control  - 37 minute mark - cults 46 minute mark Support the show

Help Us Build Better Solutions for Your Practice!

Fontes do episódio aqui: ⁠https://portal.afya.com.br/podcasts/afya-news/26-05-2026Nesta terça-feira, o boletim destaca o Dia Nacional de Combate ao Glaucoma, novos marcos terapêuticos e os desafios éticos da tecnologia na saúde. No bloco principal, reforçamos a importância do rastreio clínico oportuno do glaucoma na atenção primária para mitigar o risco de cegueira irreversível. Detalhamos a aprovação pela Anvisa do Vyalev®, uma terapêutica inovadora de infusão subcutânea contínua para o Parkinson avançado. Por fim, abordamos no Radar o alerta emitido pela The Lancet sobre o risco de a inteligência artificial ampliar as desigualdades estruturais nos sistemas de saúde. Afya News. Informação médica confiável e atualizada no seu tempo.

What if you could detect Alzheimer's years before any symptoms appeared and stop it?Dr. Yogesh Shah is a Board-Certified Geriatrician and Mayo Clinic-trained memory specialist who has spent 25 years focused entirely on the early detection and prevention of dementia. In this episode, he makes a case that every entrepreneur in their 40s and 50s needs to hear: the window to protect your brain is now. Not at 70. Not after a diagnosis.America spends 20% of its GDP on healthcare, and nearly all of it goes to disease management. Dr. Shah explains why that approach is failing, what Mild Cognitive Impairment is and why it matters, and how a new FDA-approved blood test can identify Alzheimer's pathology years before any symptoms appear. He walks through the 14 lifestyle factors identified in the Lancet study that can reduce dementia risk by up to 45%, and explains how monoclonal antibody infusions are now removing amyloid plaque from the brains of patients caught early enough.What you will walk away with: an understanding of why 40 to 50% of dementia cases go undiagnosed and the real-world consequences, what the new p-tau blood tests are and how to ask your doctor about getting one, which lifestyle factors carry the most risk weight for entrepreneurs, and why managing your LDL, sleep, social connection, and chronic conditions in midlife is the most important thing you can do for your future brain health.Connect with Dr. Yogesh Shah on LinkedIn Hosted by John St. Pierre and Rich Hoffmann, Entrepreneurs United is built for founders and leaders who want straight talk on building businesses that actually work. New episodes every week.https://entrepreneursunited.us/links/

Send us Fan MailO que você oferece nas primeiras semanas importa — e muitoQuatro estudos. Quatro perguntas que todo neonatologista e pediatra já enfrentou na prática. Voltamos a apresentar os artigos do livro 50 Estudos que Todo Neonatologista Deve Conhecer, dessa vez com os artigos que revolucionaram a nutrição neonatal.Qual fórmula dar a um prematuro quando o leite materno não está disponível? Promover o aleitamento de forma estruturada realmente muda desfechos clínicos? Leite doado é superior à fórmula para prematuros extremos? E como manejar a hipoglicemia neonatal sem separar mãe e bebê?Neste episódio da Incubadora, discutimos os ensaios de Lucas et al. no BMJ, o PROBIT no JAMA, o DoMINO no JAMA e o Sugar Babies no Lancet — estudos que, juntos, constroem um argumento difícil de ignorar: decisões tomadas nas primeiras horas e semanas de vida deixam marcas que aparecem no pulmão, no cérebro e no desenvolvimento anos mais tarde.1.     Randomised trial of early diet in preterm babies and later intelligence quotient  - https://pubmed.ncbi.nlm.nih.gov/9831573/2.     Promotion of Breastfeeding Intervention Trial (PROBIT) A Randomized Trial in the Republic of Belarus - https://pubmed.ncbi.nlm.nih.gov/11242425/3.     Effect of Supplemental Donor Human Milk Compared With Preterm Formula on Neurodevelopment of Very Low-Birth-Weight Infants at 18 Months A Randomized Clinical Trial - https://pubmed.ncbi.nlm.nih.gov/27825008/4.     Dextrose gel for neonatal hypoglycaemia (the Sugar Babies Study): a randomised, double-blind, placebo-controlled trial - https://pubmed.ncbi.nlm.nih.gov/24075361/Evidência, cuidado e contexto brasileiro — esse é o nosso roteiro. Não esqueça: você  pode ter acesso aos artigos do nosso Journal Club no nosso site: https://www.the-incubator.org/podcast-1Lembrando que o Podcast está no Instagram, @incubadora.podcast, onde a gente posta as figuras e tabelas de alguns artigos. Se estiver gostando do nosso Podcast, por favor dedique um pouquinho do seu tempo para deixar sua avaliação no seu aplicativo favorito e compartilhe com seus colegas. Isso é importante para a gente poder continuar produzindo os episódios. O nosso objetivo é democratizar a informação.Se quiser entrar em contato, nos mandar sugestões, comentários, críticas e elogios, manda um e-mail pra gente: incubadora@the-incubator.orgEvidência, cuidado e contexto brasileiro - esse é o nosso roteiro.

En la revista The Lancet publican un estudio en el que se inidca 1.200 millones de personas —un 14% de los que vivimos en este planeta— sufren problemas de salud mental. Es casi el doble de lo registrado de 1990. Los cientificos consideran que este aumento se debe a que ha mejorado la detección, pero también suponen que la pobreza enquistada, las guerras, el impacto de desastres naturales y fenómenos tan disruptores como la pandemia han disparado la incidencia de trastornos. Los adolescentes de entre 15 y 19 años y las mujeres de todas las edades soportan los niveles más altos, en particular por ansiedad y depresión.

It's In The News, where we bring you the top diabetes stories and headlines happening now. Top stories this week: Dexcom shares details of its next generation CGM, T1D and GLP-1 studies, weight loss management on GLP-1 medications updates, all-in-one CGM and pump, and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcript: XX Dexcom announces some features of it's next generation CGM – the G8. We've been talking about this with CEO Jake Leach for a while now – it will be a 50% smaller with what they're calling advanced sensing capabilities. According to Leach, G8 will adapt to the physiologic variability of each user. It has additional technology built in, based on a new silicon chip design and algorithm. 15 day wear is now the baseline for all Dexcom sensors moving forward. At launch the G8 will only measure glucose but the plan is for a multi-analyte version to follow. That would measure ketones and potassium. Ketones we know – but potassium is very important for people with kidney and possible for people taking some diabetes meds. It's an interesting space to watch.. btw, analyte is just a medical word for the specific thing you're measuring – the target of the test you're running. we're going to hear that word a lot I think..   Looks like an FDA submission for the G8 next year.. with an outside the US launch the following year. https://www.drugdeliverybusiness.com/dexcom-unveils-next-gen-g8-cgm/ XX Glucotrack has submitted its implantable continuous blood glucose monitor (CBGM) for FDA IDE, that's investigational device exemption and would enable the company to initiate a U.S. clinical study for the fully implantable technology. Rutherford, New Jersey-based Glucotrack's device features no on-body external component. The company aims to offer it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution. Unlike traditional CGMs that measure glucose in interstitial fluid, the CBGM measures glucose levels directly from the blood. The implant goes five centimeters within the subclavian vein. Glucotrack's active implantable device has a small battery and some electronics that go just under the skin in the pectoral region. The location of the implant is not in a major vessel, but the implant can measure real-time glucose levels as pulsatile blood flows over the tip of the sensor. https://www.drugdeliverybusiness.com/glucotrack-submits-long-term-implantable-cbgm-fda-ide/ XX PharmaSens today announced the publication of data from the first clinical study evaluating its all-in-one insulin patch pump offering. The all-in-one pump pairs the Niaa Essential insulin patch pump with the SynerG continuous glucose monitor (CGM) sensor developed by Pacific Diabetes Technologies. However, this system would be one device that features both the pump and CGM technology.   PharmaSens and SiBionics also have a collaboration aimed at developing the all-in-one solution. They are jointly developing the next-generation Niia insulin patch pump with a SiBionics CGM. PharmaSens expects a second feasibility study in the second quarter to evaluate the next-generation pump with SiBionics' CGM.   PharmaSens says the clinical feasibility study of Niia demonstrated for the first time ever that the combined offering is, in fact, feasible. It believes its device addresses the need for alternatives to multi-device diabetes management. systems.   Aggregated MARD for the investigational device came in at 11.6%. A MARD target of less than 10% is considered ideal for CGM devices, but PharmaSens said that, in the context of the early feasibility study, the results were encouraging and provide evidence supporting the development of an all-in-one system. https://www.drugdeliverybusiness.com/pharmasens-efs-insulin-patch-pump-cgm/ XX   XX ViCentra launches the newest version of the Kaleido pump system in Europe. This is that small colorful pump, with Diabeloops algorithm and the Dexcom G7. It'll be in Germany and the Netherlands later this summer. https://hellokaleido.com/vicentra-announces-commercial-launch-of-new-smartphone-controlled-kaleido-automated-insulin-delivery-patch-pump-system/--   XX Diabeloop just got CE Mark approval for DBLG2 integrations – it's latest AID platform the company has kicked off the gradual European launch of the technology. It currently offers DBLG2 as a smartphone application on Android, with iOS integration coming soon. As you just heard, it's integrated with kaleido and the company says it plans to make additional configuration for DBLG2 with alternative pumps "available soon." Running on a user's smartphone, DBLG2 works as a self-learning algorithm. It continuously analyzes glucose data, calculates insulin needs in real time and automatically adjusts delivery. https://www.drugdeliverybusiness.com/diabeloop-fda-next-gen-algorithm-g7/   XX Among adults with type 1 diabetes (T1D), the initiation of GLP-1-based therapy was associated with a lower risk for all-cause death, several cardiovascular outcomes, all-cause hospitalisations, and hypoglycaemia, without a higher risk for diabetic ketoacidosis.   METHODOLOGY: Researchers in Greece conducted a retrospective cohort study utilising real-world data from a global health research network to evaluate the association between GLP-1-based therapy and cardiovascular and renal outcomes in adults with T1D. A total of 4088 patients receiving GLP-1-based therapies (median age, 43 years; 34.3% men) were propensity score matched with an equal number of patients not receiving the treatment. The risk for hypoglycaemia was lower with GLP-1-based therapy (hazard ratio, 0.72; P = .021); however, the risk for diabetic ketoacidosis did not differ significantly between the two groups. https://www.medscape.com/viewarticle/glp-1-drugs-tied-cardiovascular-benefits-t1d-2026a1000fbx   XX Eli Lilly and Company (NYSE: LLY) today announced detailed results from two late-phase trials showing that people with obesity maintained their weight loss long term with either Foundayo or lower-dose Zepbound after switching from higher doses of injectable incretin therapy. The findings from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN, were presented at the 33rd European Congress on Obesity (ECO) and published in The Lancet and Nature Medicine, respectively.   "Weight regain remains one of the biggest challenges in obesity care, and is often the result of treatment interruptions that cause biology to work against patients, undoing the progress they've made," said Louis J. Aronne, M.D., FACP, DABOM, founder and Chair Emeritus of the American Board of Obesity Medicine, former president of The Obesity Society, Fellow of the American College of Physicians, world-renowned obesity specialist and Lilly consultant. "These medicines can be used for long-term maintenance today, and results from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN provide additional evidence of their potential when switching from higher doses of injectable incretin therapy." https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-and-lower-dose-zepbound-helped-people-maintain XX Scientists in Sweden have developed a more reliable way to create insulin-producing cells from human stem cells. These lab-grown cells not only respond strongly to glucose but were also able to restore blood sugar control when transplanted into diabetic mice. When transplanted into diabetic mice, the cells gradually restored the animals' ability to regulate blood sugar. Long way to go, as we say with most of these mice studies. https://www.sciencedaily.com/releases/2026/05/260505234620.htm XX Interesting look at how the body controls sugar storage – apparently this finding challenges long-standing biology concepts and could open new directions for disease treatment. Published in Nature, the study describes a potential method for directly reducing glycogen, the stored form of sugar in the body. These scientists discovered that glycogen can be directly regulated by ubiquitin, a protein best known for marking damaged proteins for recycling or removal. The study is the first to show that ubiquitin can regulate glycogen in humans, overturning more than 50 years of scientific understanding. Excess glycogen is also associated with more common health problems, including diabetes, obesity, liver disease, and heart disease.       https://scitechdaily.com/scientists-just-rewrote-biology-hidden-mechanism-could-transform-diabetes-treatment/ XX A new Oklahoma law will give parents the option to have their children screened for Type 1 Diabetes.   The measure passed with overwhelming bipartisan support in the Legislature and takes effect Nov 1. Oklahoma consistently ranks among the states with the highest rates of diabetes and diabetes-related deaths. The law gives parents access to antibody testing that can detect risk years before symptoms develop, helping families take preventive action and avoid emergency room visits. https://journalrecord.com/2026/05/11/oklahoma-law-expands-access-type-1-diabetes-screening/ XX More to come including a new study trying to figure out why some people are more likely to develop diabetes, a look at cannabis and preventing metabolic disorders, and XX   A National Institutes of Health (NIH)-funded study has identified key differences in human pancreatic islet cells that may help explain why some people are more likely to develop diabetes. Researchers found that the mix of hormone-producing cells in the pancreas varies widely from person to person, and that variation plays a central role in how the body regulates blood sugar. The study involved a deep dive into islet cell function that is linked to donor traits associated with observable characteristics, or phenotype, such as sex, race and ethnicity, as well as genetic information, or genotype, including predicted ancestry and genetic risk for both type 1 and type 2 diabetes. The findings highlight that islet cell composition, rather than the physical size and shape of islets, is a key factor in regulating hormone release. The team found that the makeup of pancreatic islets plays a major role in how effectively they release insulin and glucagon — key hormones that regulate blood glucose. Islets with a higher proportion of insulin-producing beta cells showed stronger insulin secretion in response to various stimuli, while higher levels of alpha and delta cells were generally linked to reduced insulin output. In addition, the researchers found that islet hormone secretion is affected by donor traits, such as sex, race and ethnicity and their genetic makeup, including ancestry predicted from genetic testing and genetic risk for type 2 diabetes. Combined, the findings of the study have significant implications for understanding the factors that may predispose people to diabetes. "This study is the tip of the iceberg," said Dr. Evans-Molina. "We hope this dataset becomes useful to the entire diabetes research community and that researchers use it to answer questions about the genotype-phenotype correlation within these data."   https://www.nih.gov/news-events/news-releases/nih-funded-study-maps-human-pancreatic-islet-cells-offering-new-clues-diabetes-risk XX XX XX Research published recently in JAMA Network Open offers illuminating evidence suggesting there is a positive association between GLP-1 agonists—drugs commonly used to treat obesity and diabetes—and better outcomes among breast cancer patients.   "This study suggests that GLP-1 drugs may offer protective benefits potentially improving survival and recurrence risk in some female patients with breast cancer – whether this is related to weight control, improve cardiovascular health or other mechanisms remains to be studied," said study senior author Bernard F. Fuemmeler, Ph.D., MPH, associate director for population sciences and the Gordon D. Ginder, M.D., Chair in Cancer Research at VCU Massey Comprehensive Cancer Center.   Breast cancer patients who are also obese or have type 2 diabetes experience more aggressive cancer growth and worse outcomes. Prior studies have shown that weight loss treatment and surgery following a breast cancer diagnosis are associated with improved heart health and increased survival.   What are GLP-1 drugs? Glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Approved to treat type 2 diabetes in 2005 and weight management in 2021. Impacts on breast cancer survival and recurrence are still unclear. Since 2020, the use of these drugs has increased dramatically, where approximately 12% of Americans have used GLP-1s for weight loss, according to a RAND report.   The research findings Through a retrospective cohort study examining the electronic health records of more than 840,000 breast cancer patients who were diagnosed between 2006 and 2023, the results suggest there is a potential link between GLP-1 RAs and improved outcomes among breast cancer patients who are also obese or have type 2 diabetes.   GLP-1 RA use was associated with an overall lower risk of death from any cause over a 10-year follow-up period among breast cancer patients. Additionally, breast cancer survivors who used GLP1-RAs for diabetes or obesity had a significantly lower risk of their cancer returning over 10 years following their initial treatment.   "Our findings align with emerging preclinical research and contribute to a growing body of literature related to GLP-1 RA use in oncology settings," said study lead author Kristina L. Tatum, PsyD, MS, of the VCU School of Public Health.   What's next? Further studies are needed to understand the biological mechanisms, if any, between GLP-1 RAs and breast cancer outcomes. The research team intends to further evaluate these correlations through randomized clinical trials.   "Our study underscores the potential of GLP-1 RAs as an adjunct strategy for improving cancer-related outcomes among patients with breast cancer, although clinical trials are needed to inform effective therapeutic approaches and clinical decision making," Fuemmeler said. https://www.oncology-central.com/could-glp-1-receptor-agonists-improve-outcomes-for-breast-cancer-patients-with-obesity-or-with-type-2-diabetes/ XX Researchers at UC Riverside gave cannabis to obese mice and found that not only did the rodents lose weight, but when given a concentrated cannabis oil, the mice also saw striking benefits in their metabolic function. DiPatrizio said his team studied the issue to better understand why cannabis users show significant reductions in weight and risk for diabetes compared with nonusers. "We would think that chronic cannabis users would be eating more and weigh more, but it's just the opposite," DiPatrizio said. Scientists are increasingly examining the possibility that cannabis compounds could fight obesity or metabolic disorders like diabetes. Cannabinoids interact with the body's endocannabinoid system, which partially controls nearly every aspect of our physiology, including metabolism and appetite. That creates the possibility that targeting this widespread system could unlock new therapies for these conditions. https://www.sfgate.com/cannabis/article/cannabis-weight-loss-california-study-22255328.php XX A new campaign launched by diaTribe and Genentech aims to empower and educate people about diabetes-related eye disease. Here's what you can do today to protect your eye health. To help address these barriers, diaTribe and Genentech partnered to launch All Eyes on DME, a new campaign that aims to spread awareness and educate people at-risk for or living with diabetes-related eye conditions like DME. Also partnering in the campaign is actor and comedian Damon Wayans, who wanted to share his journey (and, of course, a joke or two) with type 2 diabetes to open up the conversation about what is often a stigmatized or less talked about topic: eye health and diabetes.   One of these important conversations happened recently at the All Eyes on DME launch in New York City, where Wayans joined a panel of experts, advocates, and people living with DME to talk about diabetes-related eye disease and how to help prevent it. https://www.alleyesondme.com/dme-in-the-spotlight.html https://diatribe.org/diabetes-complications/all-eyes-dme-new-campaign-spotlights-eye-health-and-diabetes

O Afya News detalha o alerta da Anvisa para o recolhimento de lotes de atorvastatina e dexametasona ressaltando o papel da farmacovigilância na segurança do paciente. Na ortopedia analisamos as novas diretrizes da FDA para implantes customizados que exigem validação rigorosa do planejamento por imagem para otimizar o alinhamento e reduzir o tempo cirúrgico. O episódio também aborda o estudo da The Lancet sobre o distanciamento do Brasil das metas para doenças crônicas até 2030 alertando para o aumento da obesidade do diabetes e da hipertensão. Afya News. Informação médica confiável e atualizada no seu tempo.Fontes do episódio aqui:https://portal.afya.com.br/podcasts/afya-news/19-05-2026

Today's episode is a little different because there is breaking news in the women's health world, and I think this is one of the more important shifts we've seen in a long time when it comes to how we understand female physiology. As of May 12th 2026, PCOS, which stands for Polycystic Ovarian Syndrome, has officially been renamed PMOS or Polyendocrine Metabolic Ovarian Syndrome. And before anybody rolls their eyes and thinks, okay, okay, so they changed the name. I want you to stay with me for a minute here, because this matters then what most people realize.  This came from a massive international consensus published in The Lancet involving researchers, clinicians, advocacy groups, and over twenty two thousand voices globally over the course of about fourteen years. And the reason this matters is because the old name PCOS centered the conversation almost entirely around the ovaries, when clinically, the condition has always been much bigger than that. For years, women have been told you don't have cysts, your ultrasound looks normal, your labs are fine, and meanwhile they are struggling with a plethora of symptoms like fat loss, resistance, irregular cycles, acne, hair thinning, blood sugar dysregulation, fatigue, fertility issues, mood shifts, sleep disruption inflammations, and symptoms that clearly extended far beyond reproductive health alone. And what I appreciate about this shift is that the biology did not suddenly change overnight. The language finally caught up with the physiology because many women diagnosed with PCOS never had visible ovarian cysts in the first place, and many women with ovarian cysts never had PCOS. Which tells us something very important. The ovaries were never the entire story, and I've spoken of this on previous podcasts. This new terminology, polyendocrine, metabolic ovarian syndrome, reflects something we've been discussing for years inside the SF coaching method, which is that women's health is deeply interconnected. Think hormones, metabolism, stress, physiology, sleep. These do not function in isolation. Everything speaks to everything. These systems work together and this shift toward PMOS finally acknowledges the crosstalk between the endocrine system, metabolism, reproductive function, inflammation, nervous system regulation, and overall physiological health. So today I want to break down what changed and why it matters.   Time Stamps:   (0:40) Breaking News In Women's Health (3:45) Why PCOS Was Confusing (6:45) The Shift To PMOS (12:25) Names Influence Clinical Focus (20:10) Previous Women's Health Shift I Previously Covered (24:10) The Systems Lens ----------  Apply for SF Coaching Method  https://sarahfechter.ac-page.com/sfhq-cc Complimentary Health Content  https://sarahfechter.ac-page.com/Health_Wellness_Community ----------  Follow Me On Instagram - https://www.instagram.com/sarahfechter.ifbbpro/   Check Out My Website - https://www.sarahfechter.com ----------  This Podcast is for general informational purposes only and does not constitute the practice of medicine, nursing, other professional health care services, or any professional practice of any kind. Any reliance on the information provided in this Podcast is done at your own risk and Sarah Fechter Fitness LLC expressly disclaims any and all liability or responsibility for any direct, indirect, incidental, special, consequential or other damages arising out of any individual use of, reference to, reliance on, or inability to use, this Podcast or the information presented in this Podcast. All contents and design for this Podcast are owned by Sarah Fechter Fitness LLC. Always consult your professional team before beginning any exercise or nutrition program.

The ESCMID Global Late Breakers series returns to Communicable! Five CMI Communications editors – Marc Bonten, Josh Davis, Angela Huttner, Anne-Grete Märtson, and Erin McCreary – handpicked five late-breaking trials presented at ESCMID Global 2026 to summarise their  findings and discuss whether the results will change their practice. This is part one of the two-part series. Trials presented are listed below and links to their respective sessions can be watched and rewatched on the ESCMID Global Virtual Platform. Links to corresponding publications, if available, and mentioned related articles are provided as well. The FAST trial (Late-breaking research from JAMA)Banerjee R, et al. Fast Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia. The FAST Randomized Clinical Trial, doi: 10.1001/jama.2026.5487 Srinivasan A. A Multinational Trial of Rapid Antimicrobial Susceptibility Testing. Is FASTer Better?, doi: 10.1001/jama.2026.5504The CEFMEC trial (Poster session)Hayakawa K, et al. Effectiveness of cefmetazole versus meropenem for invasive urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli, Antimicrob Agents Chemother 2023, doi: 10.1128/aac.00510-23The COBRA trial (Late-breaking trials in surgical infection prevention)Overdevest AG, et al. Antibiotic treatment for 1 day versus 4-7 days in patients with acute cholangitis after adequate endoscopic biliary drainage (COBRA): study protocol for a randomized controlled trial. Trials, doi: 10.1186/s13063-026-09524-7The DOTS trial, a secondary analysis (Late-breaking research from JAMA)Lodise, TP, et al. Pharmacokinetics of Dalbavancin in Complicated Staphylococcus aureus Bacteremia: A Secondary Analysis of the DOTS Randomized Clinical Trial, JAMA 2026, doi: 10.1001/jamanetworkopen.2026.11652 Walls G, et al. Patient-reported Perceptions, Experiences, and Preferences Around Intravenous and Oral Antibiotics for the Treatment of Staphylococcus aureus Bacteremia: A Descriptive Qualitative Study, Clin Infect Dis 2026, doi: 10.1093/cid/ciaf522Turner  NA , et al.  Dalbavancin for treatment of Staphylococcus aureus bacteremia: the DOTS randomized clinical trial. JAMA 2025, doi: 10.1001/jama.2025.12543 Maribavir for clinically significant cytomegalovirus infection in hematopoietic cell transplantation: a real-world retrospective international study of the Infectious Disease Working Party of EBMT (Late-breaking research from The Lancet)Paviglianiti A, et al. Maribavir for clinically significant cytomegalovirus infection in haematopoietic cell transplant recipients in Europe: a real-world multicentre retrospective registry study. Lancet 2026. doi: 10.1016/S1473-3099(26)00144-1

Entre 1990 et 2023, le nombre de cancers chez les femmes françaises a explosé de 104% d'après une étude parue dans le magazine The Lancet. C'est le plus haut pourcentage d'Europe. Quel est le lien entre cancer et changement climatique ? Pourquoi les femmes sont-elles les plus touchées ? Et enfin, quelles responsabilités ont les pouvoirs publics dans cette situation ?Retour sur une soirée exceptionnelle en présence de la militante Camille Etienne, de la fondatrice de Cancer Colère, Fleur Breteau et du toxilocologue Xavier Coumoul. Une soirée animée par Maud Benakcha, journaliste vidéo à Libération. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Allergies have tripled - with hay fever, seasonal allergies, eczema and food intolerances now affecting millions of people. But why are allergy symptoms getting worse, and what does gut health have to do with it? In this episode, Adam Fox, a world-leading allergy Professor at King's College London, explains why allergies may be rising so fast, why many beliefs about allergies are wrong, and what new science reveals about your immune system, skin and gut. Professor Fox explores why some foods are more likely to trigger reactions, and why modern allergy science is increasingly focused on gut health. Adam also discusses why 90% of people told they are allergic to certain things may not actually be allergic, the difference between allergies and intolerances, and why some antihistamines may be doing you more harm than you realise. By the end of this episode, you will have some practical ways to manage hay fever and seasonal allergies, including which antihistamines experts now recommend avoiding, simple ways to reduce pollen exposure at home, and when allergy testing or desensitisation treatment may help. Adam explains how newer treatments are starting to retrain the immune system rather than simply suppress symptoms. If allergies barely existed a few hundred years ago, what changed? And could your gut now be shaping the way your immune system reacts to the world around you?

View This Week's Show NotesStart Your 7-Day Trial to Mobility CoachJoin Our Free Weekly Newsletter: The AmbushWhat if the biggest thing holding your health back isn't what you're doing, but how you're thinking about it? Most of us have been trained to see the body in silos: diagnose the problem, treat the symptom, move on. But what if that model is missing the bigger picture?In this episode of The Ready State Podcast, Dr. Jeffrey Bland – widely recognized as the father of functional medicine – joins Juliet and Kelly Starrett to unpack a more complete, systems-based approach to health. From a simple (and surprisingly accessible) blood test that can reveal your inflammatory status, to the real role of inflammation as both a healing response and a hidden driver of chronic disease, this conversation challenges everything you thought you knew about “being healthy.”Dr. Bland also shares the deeply personal story that reshaped his entire career and led him to question conventional medicine's focus on downstream symptoms instead of root causes.You'll walk away understanding why everyday choices – like sugar intake, sleep, stress, and even your sense of self-agency – play a far bigger role in longevity than most people realize. Because at the end of the day, health is something you actively create.What You'll Learn in This EpisodeWhy chronic inflammation is both a healing response and a hidden driver of diseaseHow a standard blood test (CBC) can reveal your body's inflammatory stateThe difference between treating symptoms vs. addressing root causes (upstream vs. downstream health)Why your body is a system – and not a set of isolated problems to fixHow everyday habits like sugar intake, stress, and sleep quietly accelerate agingKey Highlights: (0:00) Intro & Teaser Clips(0:35) Introducing Dr. Jeffrey Bland, Father of Functional Medicine(3:11) Dr. Bland Joins the Show / Earth Day Connection(3:50) How Dr. Bland's Career Began in 1970(7:33) What's Most Urgent for People to Understand About Health Today(9:13) Systems Thinking vs. Siloed Medicine(12:43) A Seismic Life Event That Changed Everything(15:19) Finding Purpose After Tragedy — The Birth of a Mission(17:35) Origins of the Term "Functional Medicine"(19:03) Functional Medicine in The Lancet — 1874(31:15) Understanding Good vs. Chronic Inflammation(38:30) The Ibuprofen Epidemic in Youth Athletes(39:59) The Functional Medicine Model: Antecedents, Triggers & Mediators(42:47) Big Bold Health & Testing for Inflammaging(43:33) The CBC with Differential — A $6 Test Everyone Already Has(45:08) The SIRI Index — Calculating Your Inflammatory Status(46:25) Immune Cells Renew Every 90–120 Days(56:03) The 850-Person Clinical Trial on Food & Immune Health(56:56) Tartary Buckwheat — A 3,500-Year-Old Immune Superfood(1:02:57) The Healthcare System Isn't Working — A Seismic Change Is Coming(1:08:13) Rapid Fire: Blue Zones & Eating a Rainbow of Polyphenols(1:09:47) The #1 Lever for Aging Well — Starting With How You See Yourself(1:10:56) Where to Find Dr. Jeff Bland & Closing ThoughtsHuge thanks to our sponsors, Kreatures of Habit, LMNT, and Momentous.

Brain Health Breakthrough Coaching Programhttps://rawfoodmealplanner.clickfunnels.com/webinar-replay-brain-health-breakthrough-coaching-programJoin RawFoodMealPlanner's 21-Day Challengehttps://rawfoodhealthempowermentsummit.com/the-rawfoodmealplanner-s-21-day-new-year-meal-prep-challenge Boost Your Wellness Journey:The Brain Reboot Plan: 5 Simple Daily Shifts for More Focus, Energy & Peacehttps://rawfoodmealplanner.com/brain-reboot-plan/Revitalize Your Brain: A Lifestyle Approach for Women Over 50https://rawfoodmealplanner.clickfunnels.com/webinar-replay-brain-health-breakthrough-coaching-programRESET: 3 Metabolic Mistakes Women 30+ Make And How to Fix Themhttps://rawfoodmealplanner.com/reset-3-metabolic-mistakes-women-30-make-and-how-to-fix-them/The Lancet published a study here https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(24)00191-0/fulltext emphasizing that young adults (ages 18–39) are a neglected but crucial window for dementia prevention. Most dementia research focuses on mid-to-late life, yet many modifiable risk factors that affect long-term brain health emerge or peak in young adulthood.Key Modifiable Risk FactorsEducation: Low levels reduce cognitive reserve and increase dementia risk.Hearing loss: One billion young adults globally are at risk due to unsafe listening practices.Traumatic brain injury (TBI): High rates from sports, motor accidents, and intimate partner violence.Hypertension: One in 12 young adults is affected; rates higher among Black Americans and in LMICs.Alcohol use: Peaks in early 20s, linked to long-term brain changes.Obesity & physical inactivity: Both rising rapidly; linked to inflammation and cardiovascular risk.Smoking/vaping: 90% of daily smokers start before 26.Depression & social isolation: Peak in early 20s, linked to later ADRD (Alzheimer's disease and related dementias) risk.Diabetes: 4% prevalence in young adults; prediabetes affects 1 in 4.Environmental factors: Air pollution, vision loss, high LDL cholesterol, and even emerging risks like sleep disruption, stress, spirituality, and microplastics.Join the Conversation:Subscribe and share this episode with anyone on their own path of health and transformation. // HOST Samantha Salmon, NBC-HWC Nationally Board Certified Health & Wellness Coach Brain Health Licensed Trainer | Integrative Nutrition Coach | Intuitive Nutrition Coach for Brain & Metabolic HealthThe information provided in this broadcast is for educational purposes only and is not intended as medical advice. These statements have not been evaluated by the Food and Drug Administration or the equivalent in your country. Any products/services mentioned are not intended to diagnose, treat, cure, or prevent disease. RawFoodMealPlanner.com © 2026

Oh, What's in a Name? Irving F. Stein and Michael L. Leventhal first described the syndrome, originally known as Stein-Leventhal syndrome, in 1935, in the AJOG. They published a case series of seven women displaying a triad of symptoms, including hirsutism, amenorrhea (absent menstruation), and bilaterally enlarged polycystic ovaries. We now know that PCOS affects 1 in 8 women globally (170 million women of reproductive age worldwide), and that there are 4 main manifestations of the condition- reflecting its diverse phenotype. Now, as of 05/12/25, a collaboration across 56 leading academic, clinical, and patient organizations, as well as iterative global surveys that garnered responses from over 14,300 people with PCOS and multidisciplinary health professionals have endorsed a NEW term (Lancet) for this: polyendocrine metabolic ovarian syndrome. This is actually STAGE 7 of an 8 stage process Yep, 1-6 are already done). But hold on…this is not taking over tomorrow! There is a THREE-YEAR implementation strategy that has already gotten started and culminating in 2028. Listen in for details.1. Teede HJ, Khomami MB, Morman R, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. Published online May 12, 2026. Accessed May 12, 2026. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00717-8/fulltext2. International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome; 20233. https://www.contemporaryobgyn.net/view/global-consensus-renames-pcos-to-polyendocrine-metabolic-ovarian-syndrome-pmos-?utm_campaign=42986360-COG%20-%20Breaking%20News&utm_medium=email&_hsenc=p2ANqtz--5Of8-OwjOeKLtknr8YdFbh9G8_c7iQqliHnMz2pYOpi2x4Pp8dRH6bSHjrQIqnth_fLPywQM2ByNp7via22VJ8yyLbg&_hsmi=418414457&utm_content=418414457&utm_source=hs_email4. Polyendocrine Metabolic Ovarian Syndrome: New name to improve diagnosis and care of condition affecting 170 million women worldwide. Monash University. News release. May 12, 2026. Accessed May 12, 2026. https://www.eurekalert.org/news-releases/1127647

As I have said many times before, some podcast ideas come from REAL clinic encounters. In this episode, Dr Hanna V, our dedicated PGY1 on our call team, and I will answer TWO real questions which arose just today on morning rounds, on our service: 1. Does NORMOTENSIVE HELLP still need Mag Sulfate? And 2. Does an indwelling foley s/p iatrogenic bladder injury at CS require prophylactic antibiotic coverage for urinary infection? Yep: It's a BOGO sale on today's podcast- Buy ONE GET ONE! Listen in for details.1. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222.Obstetrics and Gynecology. 2020. Committee on Practice Bulletins—ObstetricsGuideline2. Woudstra DM, Chandra S, Hofmeyr GJ, Dowswell T.SR. Corticosteroids for HELLP (Hemolysis, Elevated Liver Enzymes, Low Platelets) Syndrome in Pregnancy.The Cochrane Database of Systematic Reviews. 2010. 3. Joshi D, James A, Quaglia A, Westbrook RH, Heneghan MA.Liver Disease in Pregnancy. Lancet. 2010. Review4. Rimaitis K, Grauslyte L, Zavackiene A, et al.Observational. Diagnosis of HELLP Syndrome: A 10-Year Survey in a Perinatology Centre. International Journal of Environmental Research and Public Health. 20195. Reau N, Munoz SJ, Schiano T.Guideline Liver Disease During Pregnancy.The American Journal of Gastroenterology. 2022. 6. ACG Clinical Guideline: Liver Disease and Pregnancy.The American Journal of Gastroenterology. 2016. Tran TT, Ahn J, Reau NS.7. ACOG Practice Bulletin No. 195: Prevention of Infection After Gynecologic Procedures. Obstetrics and Gynecology. 2018. Committee on Practice Bulletins—Gynecology Guideline8. Niels Johnsen, Hunter Wessells, Krystal Archer-Arroyo, et al. Best Practices Guidelines Management of Gentiunrinary Injuries.American College of Surgeons (2025). 20259. Fletke KJ, Jeong DH, Herrera AV . Urinary Catheter Management. American Family Physician. 2024..

For decades, a tight carotid stenosis felt like a ticking time bomb — a plaque waiting to throw an embolus and cause the next stroke. We were taught that severe narrowing meant surgery, and trials like ACAS and ACST-1 seemed to prove it. But medicine has changed. Statins, antiplatelets, tighter blood pressure control, even PCSK9 and GLP-1 therapies have quietly slashed stroke risk, and now newer data from CREST-2 suggest that for many asymptomatic patients, the knife — or the stent — may not add much at all. So if modern medical therapy works better than ever… who actually benefits from intervention anymore? Today, we unpack the evidence, the controversies, and how to counsel the patient who feels perfectly fine but has high-grade stenosis.Hosts: Carolyn Judge, Andrew Huang, Luciano Delbono, Frank Davis, Robert BeaulieuInstitution: University of Michigan, Department of Surgery, Section of Vascular SurgeryLearning objectives: Describe how modern intensive medical therapy has transformed the natural history of asymptomatic carotid stenosis and explain why contemporary patients experience substantially lower annual stroke risk than those in earlier eras. Interpret and compare the results of landmark trials—including ACAS, ACST-1, and CREST-2—to assess the relative benefits of medical therapy, endarterectomy, and stenting. Apply current evidence and guideline recommendations to patient care by selecting which asymptomatic patients are most likely to benefit from carotid revascularization versus optimized medical therapy alone. References:SVS Guidelines:Brook, R. D., et al. (2022). Society for Vascular Surgery clinical practice guidelines for management of extracranial carotid artery disease. Journal of Vascular Surgery, 75(1), e1–e67. https://doi.org/10.1016/j.jvs.2021.09.031CREST (1)Brott, T. G., Hobson, R. W., Howard, G., et al. (2010). Stenting versus endarterectomy for treatment of carotid-artery stenosis. New England Journal of Medicine, 363(1), 11–23. https://doi.org/10.1056/NEJMoa0912321CREST-2Brott, T. G., Howard, G., Fong, P., et al. (2024). Randomized trial of carotid artery stenting or carotid endarterectomy vs best medical therapy for asymptomatic carotid stenosis: CREST-2 results. [Manuscript in preparation]. ClinicalTrials.gov Identifier: NCT02089217. Retrieved from https://clinicaltrials.gov/ct2/show/NCT02089217ACST-1Halliday, A., Mansfield, A., Marro, J., et al. (2004). Randomised trial of carotid artery surgery for asymptomatic stenosis. Lancet, 363(9420), 1491–1502. https://doi.org/10.1016/S0140-6736(04)16153-1ACST-2Halliday, A., Bulbulia, R., Bonati, L. H., et al. (2021). Carotid artery stenting versus carotid endarterectomy in patients with asymptomatic carotid stenosis (ACST-2): A randomised trial. Lancet, 398(10291), 1065–1073. https://doi.org/10.1016/S0140-6736(21)01980-1ACASExecutive Committee for the Asymptomatic Carotid Atherosclerosis Study. (1995). Endarterectomy for asymptomatic carotid stenosis. JAMA, 273(18), 1421–1428. https://doi.org/10.1001/jama.1995.03520420033036Sponsor URL: https://www.goremedical.com/Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium: https://behindtheknife.org/premiumOral Board Review: https://behindtheknife.org/oral-boardOral Board Simulator: https://behindtheknife.org/oral-board/simulatorGeneral Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Saving lives is a choice, and that makes it hard for humanitarianism to be completely apolitical despite long-running debates about neutrality and impartiality. But what does being political look like? On this episode: Flotillas and White Helmets, the difference between speaking out as individual humanitarian actors or as a unified collective, moving beyond simply being in "solidarity with communities", and finding a diversity of voices to build a future version of humanitarianism. Guests:  Shatha Elnakib, faculty and deputy director of the Center for Humanitarian Health at Johns Hopkins University, and lead author of The Lancet's article, The humanitarian system: politics can not be avoided. Jonathan Whittall, executive director and founder of the KEYS Initiative Got a question or feedback? Email podcast@thenewhumanitarian.org or post on social media using the hashtag #RethinkingHumanitarianism.  

Brain Health Breakthrough Coaching Programhttps://rawfoodmealplanner.clickfunnels.com/webinar-replay-brain-health-breakthrough-coaching-programJoin RawFoodMealPlanner's 21-Day Challengehttps://rawfoodhealthempowermentsummit.com/the-rawfoodmealplanner-s-21-day-new-year-meal-prep-challenge Boost Your Wellness Journey:The Brain Reboot Plan: 5 Simple Daily Shifts for More Focus, Energy & Peacehttps://rawfoodmealplanner.com/brain-reboot-plan/Revitalize Your Brain: A Lifestyle Approach for Women Over 50https://rawfoodmealplanner.clickfunnels.com/webinar-replay-brain-health-breakthrough-coaching-programRESET: 3 Metabolic Mistakes Women 30+ Make And How to Fix Themhttps://rawfoodmealplanner.com/reset-3-metabolic-mistakes-women-30-make-and-how-to-fix-them/The Lancet published a study here https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(24)00191-0/fulltext emphasizing that young adults (ages 18–39) are a neglected but crucial window for dementia prevention. Most dementia research focuses on mid-to-late life, yet many modifiable risk factors that affect long-term brain health emerge or peak in young adulthood.Key Modifiable Risk FactorsEducation: Low levels reduce cognitive reserve and increase dementia risk.Hearing loss: One billion young adults globally are at risk due to unsafe listening practices.Traumatic brain injury (TBI): High rates from sports, motor accidents, and intimate partner violence.Hypertension: One in 12 young adults is affected; rates higher among Black Americans and in LMICs.Alcohol use: Peaks in early 20s, linked to long-term brain changes.Obesity & physical inactivity: Both rising rapidly; linked to inflammation and cardiovascular risk.Smoking/vaping: 90% of daily smokers start before 26.Depression & social isolation: Peak in early 20s, linked to later ADRD (Alzheimer's disease and related dementias) risk.Diabetes: 4% prevalence in young adults; prediabetes affects 1 in 4.Environmental factors: Air pollution, vision loss, high LDL cholesterol, and even emerging risks like sleep disruption, stress, spirituality, and microplastics.Join the Conversation:Subscribe and share this episode with anyone on their own path of health and transformation. // HOST Samantha Salmon, NBC-HWC Nationally Board Certified Health & Wellness Coach Brain Health Licensed Trainer | Integrative Nutrition Coach | Intuitive Nutrition Coach for Brain & Metabolic HealthThe information provided in this broadcast is for educational purposes only and is not intended as medical advice. These statements have not been evaluated by the Food and Drug Administration or the equivalent in your country. Any products/services mentioned are not intended to diagnose, treat, cure, or prevent disease. RawFoodMealPlanner.com © 2026

Read my article herehttps://www.linkedin.com/pulse/how-childhood-experiences-shape-pregnancy-health-salmon-nbc-hwc-ts9ge Brain Health Breakthrough Coaching Programhttps://rawfoodmealplanner.clickfunnels.com/webinar-replay-brain-health-breakthrough-coaching-programJoin January 2027 RawFoodMealPlanner's 21-Day Challengehttps://rawfoodhealthempowermentsummit.com/the-rawfoodmealplanner-s-21-day-new-year-meal-prep-challenge Boost Your Wellness Journey:The Brain Reboot Plan: 5 Simple Daily Shifts for More Focus, Energy & Peacehttps://rawfoodmealplanner.com/brain-reboot-plan/Revitalize Your Brain: A Lifestyle Approach for Women Over 50https://rawfoodmealplanner.clickfunnels.com/webinar-replay-brain-health-breakthrough-coaching-programRESET: 3 Metabolic Mistakes Women 30+ Make And How to Fix Themhttps://rawfoodmealplanner.com/reset-3-metabolic-mistakes-women-30-make-and-how-to-fix-them/The Lancet published a study here https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(24)00191-0/fulltext emphasizing that young adults (ages 18–39) are a neglected but crucial window for dementia prevention. Most dementia research focuses on mid-to-late life, yet many modifiable risk factors that affect long-term brain health emerge or peak in young adulthood.Key Modifiable Risk FactorsEducation: Low levels reduce cognitive reserve and increase dementia risk.Hearing loss: One billion young adults globally are at risk due to unsafe listening practices.Traumatic brain injury (TBI): High rates from sports, motor accidents, and intimate partner violence.Hypertension: One in 12 young adults is affected; rates higher among Black Americans and in LMICs.Alcohol use: Peaks in early 20s, linked to long-term brain changes.Obesity & physical inactivity: Both rising rapidly; linked to inflammation and cardiovascular risk.Smoking/vaping: 90% of daily smokers start before 26.Depression & social isolation: Peak in early 20s, linked to later ADRD (Alzheimer's disease and related dementias) risk.Diabetes: 4% prevalence in young adults; prediabetes affects 1 in 4.Environmental factors: Air pollution, vision loss, high LDL cholesterol, and even emerging risks like sleep disruption, stress, spirituality, and microplastics.Join the Conversation:Subscribe and share this episode with anyone on their own path of health and transformation. // HOST Samantha Salmon, NBC-HWC Nationally Board Certified Health & Wellness Coach Brain Health Licensed Trainer | Integrative Nutrition Coach | Intuitive Nutrition Coach for Brain & Metabolic HealthThe information provided in this broadcast is for educational purposes only and is not intended as medical advice. These statements have not been evaluated by the Food and Drug Administration or the equivalent in your country. Any products/services mentioned are not intended to diagnose, treat, cure, or prevent disease. RawFoodMealPlanner.com © 2026

#腸躁症 與 #消化不良 是臨床上常見的腸胃疾病，最新一集的Podcast將用兩篇《 刺胳針》(The Lancet)以及一篇《新英蘭醫學期刊》(NEJM)發表的文獻，帶大家全面認識這些功能性腸胃疾病，解析這類疾病如何受到生理及心理因素的影響！雖然這些疾病經常跟身心狀態有關，但臨床診斷仍需由「腸胃科」醫師主導，才能判斷實際的病況以及提供更加合適的治療！本集的Podcast將全面的介紹：1️⃣功能性腸胃疾病（Functional Gastrointestinal Disorders, FGID）►在流行病學上，哪像族群的風險較高？有哪些危險因子？►發病機制為何？需要補充益生菌嗎？►真的是心理因素影響到腸道嗎？2️⃣腸躁症（Irritable Bowel Syndrome, IBS） ►甚麼是腸躁症？竟然還分成「便祕型」、「腹瀉型」或「混合型」►全球以及台灣發病的盛行率又是如何？►急性腸道感染、腸道微生物群以及腦腸軸的功能異常，都是可能的致病因素！►有哪些飲食以及藥物的治療建議？ 3️⃣功能性消化不良（Functional Dyspepsia, FD） ►不明原因的上腹痛、灼熱感、餐後飽脹或噁心都是可能的症狀。►心理上的焦慮或憂鬱，以及生理上的腸躁症或胃食道逆流也是常見的共病！►近年來免疫反應的新發現！➡️功能性消化不良與 「TH2 免疫反應」有關，在患者的十二指腸中常觀察到嗜酸性球與肥大細胞增多的發炎現象，這種局部發炎會透過迷走神經影響大腦，引發情緒困擾與疼痛感。►又要如何去鑑別診斷以及治療呢？ 不論您是腸胃疾病相關的專業醫事人員，或是因為這類疾病深受其擾的人，收聽完這集Podcast將會讓您對這些腸胃疾病有更全面的認識，並獲得更明確的改善方向！立即來收聽⬇️探索大腦的會談地圖｜功能性消化不良與腸躁症收聽連結：https://linktr.ee/digital_biolab-

Paternal postpartum depression affects approximately 10% of fathers—yet it remains widely under-recognized and underdiagnosed.In this episode, we break down the research behind men's postpartum mental health, including findings from studies published in Journal of the American Medical Association, JAMA Pediatrics, and The Lancet.You'll learn:​When symptoms are most likely to appear (hint: not immediately after birth)​How depression presents differently in men​The connection between maternal and paternal mental health​The long-term impact on child development​Evidence-based ways to support new fathers ​⸻

The belief that IV dextrose is necessary to clear ketones in hyperemesis gravidarum originated from a logical, and now known to be outdated, extrapolation of basic starvation ketosis physiology and the treatment paradigm for diabetic ketoacidosis (DKA). The original experiments that led to this conclusion go back to the 1960s (Foster data). Not only is this outdated, but it is also physiologically incorrect. We've learned a lot about IV fluid replacement about hyperemesis gravidarum in the last several years- in the last data review was in January 2026 in Lancet. Even the correction of hyponatremia has evolved. Should we be following urine ketones for patients being treated for HG? Is Dextrose needed? Listen in for details.1. Nana M, Painter R, Williamson C et al. Hyperemesis gravidarum. The Lancet, Jan 2026; 407, 78-892. Clark SM, Zhang X, Goncharov DA. Inpatient Management of Hyperemesis Gravidarum. Obstet Gynecol. 2024 Jun 1;143(6):745-758. doi: 10.1097/AOG.0000000000005518. Epub 2024 Feb 1. PMID: 38301258.3. Ayus JC, et al.Correction rates and clinical outcomes in hospitalized adults with severe hyponatremia: a systematic review and meta-analysis. JAMA Intern Med. 2025;185(1):38-51. 4. ACOG Clinical Epert Series: Inpatient Management of Hyperemesis Gravidarium. Obstet Gynecol; 2024

In 1998, a British doctor, Andrew Wakefield, published a paper in the medical journal The Lancet that suggested a possible link between the MMR vaccine and the development of autism, alongside bowel problems. He pointed to what he said was a pattern: children developing normally, receiving the vaccine, and then experiencing a loss of skills. The paper was later retracted. Wakefield was denounced as a fraud and he was struck off the medical register. Now, nearly 30 years later, the mother of one of the children in Wakefield's study has decided to speak out. Paula Aitken's son Colin was known as Child Number Four. In a bombshell interview Paula tells Richie why she believes her son's autism was triggered by antibiotics, not just vaccines and that Andrew Wakefield's study was in fact a front for a sinister agenda, an agenda so dangerous that people have been murdered to ensure it never comes to light. Do NOT miss this show. 

In this week's episode we interview Kinanah Yaseen, MD, a rheumatologist from Cleveland Clinic's department of rheumatic and immunologic diseases about using ultrasound for giant cell arteritis. ·        Intro by Adam J. Brown, MD 0:12 ·        Dr. Brown's recent patient 1:34 ·        History of ultrasound and GCA 3:20 ·        Episode overview 7:05 ·        History of echolocation; how bats helped us invent ultrasound 8:00 ·        What is a bat bomb? 14:56 ·        How the Titanic helped us invent ultrasound 16:48 ·        Neurologists bring ultrasound to medicine 20:09 ·        OB/GYN is next to use ultrasound 23:11 ·        Ultrasound image quality becomes better 26:32 ·        Ultrasound use in giant cell arteritis 28:44 ·        Welcome Kinanah Yaseen, MD 33:49 ·        Using ultrasound in the clinic 34:25 ·        Can you walk us through an ultrasound of the axillary and vertebral arteries? 37:16 ·        Can you tell us why we stopped looking for sites to biopsy by finding narrowing of the vessels?  38:19 ·        Tell us about the halo sign 39:10 ·        How do you validate your ultrasound skills? 40:20 ·        If we start a patient on steroids, how useful is an ultrasound? 42:35 ·        Episode summary 44:20 ·        Thank you for listening 45:57 We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum. Kinanah Yaseen, MD, is a is a staff member of Cleveland Clinic's department of rheumatic and immunologic diseases. References: Friedman, G, et al.Isr J Med Sci. 1988 Kaproth-Joslin K A, et al. Radiographics. 2015 ;doi:10.1148/rg.2015140300 Puéchal X, et al. Lancet. 1995;doi:10.1016/s0140-6736(95)92626-7 Schmidt W A, et al. Lancet. 1995;doi:10.1016/s0140-6736(95)93005-1 Sigel B. Ultrasound Med Biol. 1998;doi:10.1016/s0301-5629(97)00264-0 Editor's Note: This has been updated to include references.

What if one of the biggest health threats on Earth… is something you can't see, taste, or even fully measure yet? In this urgent solo episode, Darin breaks down the rapidly escalating crisis of microplastics and nanoplastics infiltrating our bodies, water systems, and environment. What was once dismissed is now being acknowledged at the highest levels, with government agencies scrambling to understand and contain the damage. From plastics crossing the blood-brain barrier to disrupting hormones and carrying toxic chemicals deep into human tissue, this episode exposes the hidden cost of modern convenience, and more importantly, gives you practical, immediate actions you can take to protect yourself and your family. What You'll Learn Why microplastics are now considered a global health emergency How plastics accumulate in your body and environment The shocking truth about nanoplastics crossing the blood-brain barrier How plastics act as endocrine disruptors affecting hormones The connection between plastics and inflammation, fertility, and disease Why tap water and bottled water are both major exposure sources The role of PFAS ("forever chemicals") in long-term health damage How to filter and detox microplastics from your body Emerging science on breaking down plastics using bacteria and plants Simple, actionable steps to dramatically reduce your exposure Chapters 00:00:00 – Welcome to SuperLife 00:02:12 – Opening: committing to a clean, conscious life 00:02:27 – Fatal conveniences and why awareness matters 00:02:46 – Government officially flags microplastics as a crisis 00:03:04 – $100M+ initiatives to understand plastic contamination 00:03:38 – Microplastics in drinking water and daily exposure 00:04:20 – Plastics found in babies and human brains 00:04:45 – Why we still don't understand the full damage 00:05:08 – Nanoplastics crossing the blood-brain barrier 00:05:33 – Plastics as endocrine disruptors 00:06:02 – Hormonal imbalance, inflammation, and toxicity 00:06:30 – PFAS and the "forever chemical" crisis 00:06:59 – The #1 rule: stop using single-use plastic bottles 00:07:27 – Hidden dangers of "BPA-free" plastics 00:07:58 – Why you can no longer trust tap water 00:08:30 – The importance of high-quality water filtration 00:09:11 – Reverse osmosis systems and best practices 00:10:17 – Detox strategies: sweating and sauna use 00:10:59 – Fiber and plant-based diets binding toxins 00:11:24 – Medicinal mushrooms and beta glucans 00:11:52 – Microbes that break down plastic polymers 00:12:32 – Plant-based flocculants (okra, fenugreek) removing plastics 00:13:20 – Bio-sponges and advanced filtration innovations 00:13:46 – Magnetic separation technology 00:14:27 – Microplastics from clothing and laundry systems 00:15:16 – AI-assisted filtration and regulatory changes 00:15:55 – Light-activated breakdown of plastics 00:16:03 – Boiling water to remove up to 90% of microplastics 00:16:33 – Practical emergency water filtration methods 00:16:59 – Creating a low-toxicity lifestyle at home 00:17:20 – Final message: take control and protect your health 00:17:32 – Outro     Thank You to Our Sponsors Tru Niagen – Boost NAD+ levels for cellular health and longevity. Get 20% off with code DARIN20 at truniagen.com. Shakeology – Shakeology-All in One Nutrition: Get 15% off with code SUPERLIFE at Shakeology.com.     Join the SuperLife Patreon: This is where Darin now shares the deeper work: - weekly voice notes - ingredient trackers - wellness challenges - extended conversations - community accountability - sovereignty practices Join now for only $7.49/month at https://patreon.com/darinolien     Connect with Darin Olien: Website: darinolien.com Instagram: @darinolien Book: Fatal Conveniences Platform & Products: superlife.com New Show: Roadmap to Happiness     Key Takeaway: "We are living in a world where convenience has quietly introduced toxins into nearly every aspect of our lives, but you are not powerless. The moment you become aware, you can take action. And the small choices you make every day: what you drink from, how you filter your water, what you put into your body, can dramatically shift your long-term health and your family's future."     Bibliography/Sources: The News Hook — EPA CCL6 & STOMP Initiative Chemical & Engineering News. (2026, April 3). US government targets microplastics for research and potential drinking-water regulation. American Chemical Society. https://cen.acs.org Environmental Protection Agency. (2026, April 2). EPA takes bold action to ensure drinking water is safe from microplastics, pharmaceuticals, and potential hidden contaminants [Press release]. https://www.epa.gov/newsreleases Environmental Protection Agency & Department of Health and Human Services. (2026, April 2). EPA, HHS announce historic actions to protect Americans from microplastics and safeguard drinking water [Press release]. https://www.epa.gov/newsreleases Inside Climate News. (2026, April 3). EPA flags microplastics as 'priority' water contaminants, but the move doesn't guarantee regulation. https://insideclimatenews.org National Public Radio. (2026, April 2). EPA flags microplastics, pharmaceuticals as contaminants in drinking water. https://www.npr.org STAT News. (2026, April 2). EPA to put microplastics on study list of contaminants in drinking water. https://www.statnews.com The New Lede. (2026, April 2). EPA flags microplastics as 'priority' contaminants in drinking water. https://thenewlede.org U.S. Government. (2026). Public comment docket: EPA-HQ-OW-2022-0946. https://www.regulations.gov The Science — Brain Invasion & Cellular Damage ACS Environment & Health. (2025). Neurotoxicity of micro- and nanoplastics: A comprehensive review of CNS impacts. American Chemical Society. https://pubs.acs.org Journal of Nanobiotechnology. (2025). Maternal nanoplastic exposure led to impaired neuronal development in the fetal cortex. Springer Nature. PubMed Central. (2023). Micro-/nanoplastics breach the blood-brain barrier: Biomolecular corona's role revealed. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov PubMed Central. (2024). A review on micro- and nanoplastics in humans: Translocation of barriers and potential health effects. National Institutes of Health. https://pubmed.ncbi.nlm.nih.gov PubMed Central. (2025). Overall effects of microplastics on brain. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov ScienceDirect. (2025). Mechanisms of micro- and nanoplastics on blood-brain barrier crossing and neurotoxicity. Elsevier. https://www.sciencedirect.com The Science — Endocrine Disruption & Gut Health eClinicalMedicine. (2026). Phthalates attributed to nearly 2 million preterm births globally. The Lancet. Frontiers in Cellular and Infection Microbiology. (2024). Microplastics, human health, and the gut microbiome. Frontiers. https://www.frontiersin.org Frontiers in Endocrinology. (2023). A review of the endocrine disrupting effects of micro and nano plastic in mammals. Frontiers. International Journal of Molecular Sciences. (2025). Micro- and nanoplastics as disruptors of the endocrine system. MDPI. https://www.mdpi.com PubMed Central. (2025). Microplastics, endocrine disruptors, and oxidative stress. National Institutes of Health. Solutions — Filtration & Global Removal Technologies ACS Applied and Environmental Microbiology. (2024). Eco-microbiology: Discovering biochemical enhancers of PET biodegradation by Piscinibacter sakaiensis. American Chemical Society. ACS Omega. (2025). Thermostability and activity improvements of PETase from Ideonella sakaiensis. American Chemical Society. Environmental Science & Technology Letters. (2024). Drinking boiled tap water reduces human intake of nanoplastics and microplastics. American Chemical Society. https://doi.org/10.1021/acs.estlett.4c00081 Srinivasan, R., et al. (2025). Fenugreek and okra polymers as treatment agents for the removal of microplastics from water sources. ACS Omega. https://doi.org/10.1021/acsomega.4c07476 Yoshida, S., et al. (2016). A bacterium that degrades and assimilates poly(ethylene terephthalate). Science.  

A career in surgery has a profound impact on those who practice the craft. High rates of poor mental health are well described but incompletely understood. One potential mechanism for advancing our understanding of surgeon well-being is studying surgeons' emotional experiences. Shame, a self-conscious emotion reflecting how an individual feels about themselves, could be a particularly powerful lens. In this series on shame in surgery, we explore what we know about shame in surgery and what shame can tell us about learning and working as surgeons.In this first episode, we talk with Dr. Will Bynum and Professor Luna Dolezal about how they understand shame in medicine, why it's so hard to see even when it's everywhere, and how developing what they call "shame competence" might be one of the most important steps we can take toward humanizing surgical training.Host: Steven ThorntonGuests: Will Bynum (Associate Professor of Family Medicine, Duke University) Luna Dolezal (Professor of Philosphy and Medical Humanities, Exeter University) Publications Discussed: Dolezal L, Bynum W. Shame competence: addressing the effects of shame in health care. Lancet. 2024 Oct 19;404(10462):1514-1515. doi: 10.1016/S0140-6736(24)02269-4. PMID: 39426826. https://pubmed.ncbi.nlm.nih.gov/39426826/ The Nocturnists. Shame in Medicine: The Lost Forest [podcast series]. The Nocturnists; 2022. https://thenocturnists.org/shameinmedicine Nguyen LN, Bynum WE 4th. When I Say…self-conscious emotions. Med Educ. 2021 Mar;55(3):291-292. doi: 10.1111/medu.14425. Epub 2020 Dec 23. PMID: 33289140. https://pubmed.ncbi.nlm.nih.gov/33289140/ Tracy, J. L., Robins, R. W., & Tangney, J. P. (Eds.). (2007). The self-conscious emotions: Theory and research. The Guilford Press. ***Fellowship Application Link: https://forms.gle/QSUrR2GWHDZ1MmWC6Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium:General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewOral Board Simulator: https://app.behindtheknife.org/oral-board-simulatorTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Welcome back to the AI journal club! In this episode, we bring you a deep dive into a game-changing paper from The Lancet -- the MASAI study. This is the first randomized controlled trial to evaluate the use of artificial intelligence in breast cancer screening and we're so excited to discuss it.We'll break down the study's impressive findings on interval cancer rates, sensitivity, and massive workload reductions for radiologists. Beyond the data, we'll tackle the big-picture questions and some sensational recent headlines. Are we deploying AI too fast? Or is it time to go faster? Hosts: - Ayman Ali, MDAyman Ali is a Behind the Knife fellow and general surgery PGY-4 at Duke Hospital in his academic development time where he focuses on data science, artificial intelligence, and surgery. - Ruchi Thanawala, MD: @Ruchi_TJRuchi Thanawala is an Associate Professor of Informatics and Thoracic Surgery at Oregon Health and Science University (OHSU) and founder of Firefly, an AI-driven platform that is built for competency-based medical education. In addition, she is the Director of the Surgical Data and Decision Sciences Lab for the Department of Surgery at OHSU and Associate Program Director for the Clinical Informatics Sub-specialty Fellowship. - Phillip Jenkins, MD: @PhilJenkinsMDPhil Jenkins is a general surgery PGY-4 at Oregon Health and Science University and a National Library of Medicine Post-Doctoral fellow pursuing a master's in clinical informatics.***Fellowship Application Link: https://forms.gle/QSUrR2GWHDZ1MmWC6Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium:General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewOral Board Simulator: https://app.behindtheknife.org/oral-board-simulatorTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US